Analysis of the role of lipids in retrovirus transduction by Mukherjee, Nimisha Gupta
  



























In Partial Fulfillment 
Of the Requirements for the Degree 



































Approved by:   
   
Dr. Joseph M. Le Doux, Advisor 
Department of Biomedical Engineering 
Georgia Institute of Technology and Emory 
University 
 Dr. Mark R. Prausnitz 
Department of Chemical Engineering 
Georgia Institute of Technology 
   
Dr. Ravi V. Bellamkonda 
Department of Biomedical Engineering 
Georgia Institute of Technology and Emory 
University 
 Dr. Trent Spencer 
Department of Pediatrics 
Emory University, School of Medicine 
   
Dr. Andrew L. Lyon 
Department of Chemistry and Biochemistry 
Georgia Institute of Technology 
  
















To my wonderful family:  
 




For my loving husband, Neil 
  
ACKNOWLEDGMENTS 
  During my time at Georgia Tech, I have had the opportunity to interact with 
some very talented people.  One such person has been my advisor, Joe Le Doux.  From 
the time I stepped into his lab, he has guided me and encouraged me to think 
independently.  Over the past few years, he has taught me how to critically analyze my 
data and present it accurately.  In the process, I have had the chance to see the 
dedication and commitment Joe has to science and research, and I was and always will 
be motivated by him.  Working with Joe has taught me that research can be a creative 
process and it is never as ‘straight-forward’ as you think it is!    
 I would also like to thank my committee members, Dr. Bellamkonda, Dr. 
Prausnitz, Dr. Spencer and Dr. Lyon.  They have taken a personal interest in many 
different components of my research and I thank you for your guidance and support.  I 
would also like to thank IBB staff: Allen, Tracie, Chris R., Steve W., for always being kind 
and generous with their time and helping me especially this past year.    
 Over the years, I have had the chance to interact with many wonderful people, 
and they really have made my experience at Georgia Tech unforgettable.  I could not 
have had a better group of lab mates to learn and laugh with on many occasions: 
Natalia, Delfi, Jamie and Cindy.   Thank you Natalia for being so kind, Delfi for your 
audible laughter, Jamie for always being there and Cindy for being my ‘work spouse’ 
(Nindy).  Hours of FCS and confocal microscopy and battle for the lab temperature 
control could not have been accomplished (or won) without you.  I have learned so much 
from all of you and something tells me that the good times are not over yet!      
 Research is a dynamic process, and I would like to thank some very important 
people for helping me enjoy life when times were good and also when times got tough.   
I would like to thank Sarah, Richard, Marcus, Maxine, Heather P., Gustavo, John, Mary, 
C-Dub, Hillary, Allison, Jesse, Andrea, Brian, Jeff, Diane, Stacey, Adam, Heather B. and 
  
George.  Thank you for being such wonderful friends and I hope we find many excuses 
to see each other – MLK weekend style!  You all have been an integral part of my life 
and I am so thankful to have built life long friendships with you.   
 Last but not least, I would like to thank my family.  I really can’t put into words 
what they mean to me or the magnitude of their contribution, but I will try.  Their 
unwavering love and support was the foundation that allowed me to pursue my goals 
and follow my dreams.   I have turned to them in my times of need, whatever it may be, 
and they have always patiently listened and supported me.  My Father is my inspiration.  
He has not only encouraged me to pursue my goals in life but also set an example and 
showed me that the path is never easy.  My Mom is my greatest guide and I could not 
have come this far in life without her love and support (and her care packages that were 
many a time sent to the package cage!).   Abhishek, thank you for being my number #1 
cheerleader.  You continually amaze me with your hard work and dedication and, I 
sometimes forget who is older and wiser!  Also, thank you for filling my life with 
unforgettable memories, especially ones surrounding a particular quesadilla maker and 
mom’s growth-stunted cactus plant.   I am thankful to my new family, the Mukherjees 
who have been a constant source of love and support.  They have shared in all my 
victories (big and small) and have supported me throughout the years.   
 Finally, I would like to thank my husband, Neil.  He has been my anchor, my 
best-friend and I could not have done any of this without him.  He has made me laugh in 
my most serious times and I can’t thank him enough for always believing in me.  I am 




TABLE OF CONTENTS 
 
LIST OF TABLES ..........................................................................................................VIII 
 
LIST OF FIGURES ..........................................................................................................IX 
 
SUMMARY  ................................................................................................................XII 
  
 
CHAPTER 1: BACKGROUND AND OBJECTIVES .......................................................... 1 
1.1  Gene Therapy ............................................................................................................ 1 
1.2  Recombinant Retroviruses as Gene Delivery Vectors ............................................... 2 
1.3  Retrovirus Production................................................................................................. 4 
1.4  Retrovirus Infection .................................................................................................... 6 
1.5   Insertional Mutagenesis Concerns in Retrovirus and Lentivirus Vectors .................. 7 
1.6   Lipid Composition of Virus Particles........................................................................ 10 
1.7   Approaches to Retrovirus Targeting ....................................................................... 12 
1.8   Thesis Objectives.................................................................................................... 18 
1.9   Organization of the Thesis ...................................................................................... 19 
1.10  Outcomes and Contributions.................................................................................. 20 
1.11   References............................................................................................................ 21 
 
CHAPTER 2: RAPID MODIFICATION OF BIOLOGICAL NANOPARTICLES USING 
LIPID CONJUGATES...................................................................................................... 28 
2.1  Abstract .................................................................................................................... 28 
2.2  Introduction ..............................................................................................................28 
2.3  Materials and methods............................................................................................. 31 
2.4  Results ..................................................................................................................... 37 
2.5  Discussion................................................................................................................48 
2.6  References............................................................................................................... 51 
 
CHAPTER 3: ALTERATION OF VIRAL LIPID COMPOSITION BY MYRIOCIN 
REDUCES RETROVIRUS INFECTIVITY  ..................................................................... 55 
3.1  Abstract .................................................................................................................... 55 
3.2  Introduction ..............................................................................................................55 
3.3  Materials and methods............................................................................................. 57 
3.4  Results ..................................................................................................................... 65 
3.5  Discussion................................................................................................................92 
3.6  References............................................................................................................... 96 
 vi 
 
CHAPTER 4:  ALTERATION OF VIRAL COMPOSITION BY FUMONISIN B-1 
INCREASES RETROVIRAL INFECTIVITY AND REDUCES VIRUS BUDDING............ 98 
4.1  Abstract .................................................................................................................... 98 
4.2  Introduction ..............................................................................................................98 
4.3  Materials and methods........................................................................................... 100 
4.4  Results ...................................................................................................................108 
4.5  Discussion.............................................................................................................. 132 
4.6  References............................................................................................................. 135 
 
CHAPTER 5: CONCLUSIONS AND FUTURE RESEARCH ........................................ 137 
5.1  Summary of Results............................................................................................... 137 
5.2  Conclusions............................................................................................................ 138 
5.3  Future Considerations............................................................................................ 139 
 
APPENDIX….. ............................................................................................................. 145 
A.1 Experimental Protocol: Development of Biotin ELISA assay.................................. 145 
A.2  Radius of Gyration Approximation using Asymmetrical Field-Flow Fractionation ..146 
B.1  Technological Innovation: Generating Economic Results (TI:GER) ...................... 148 
 
 vii 





1.1 Key Features of Recombinant Retroviruses and Lentiviruses ................................... 5 













1.1 Production of recombinant retroviruses ..................................................................... 8 
1.2  Transduction of target cells by recombinant retroviruses........................................... 9 
1.3 Fusion between virus and cell lipid membrane ........................................................ 13 
1.4  Lipid raft composition in cell lipid bilayer .................................................................. 15 
 
CHAPTER 2 
2.1  Structure of DSPE-PEG-biotin ................................................................................ 38 
2.2  (A) The DSPE-PEG-biotin lipid conjugate co-purifies with retroviruses.  ................ 39 
2.2  (B) The DSPE-PEG-biotin lipid conjugate co-purifies with retroviruses.  ................ 40 
2.3  (A-D) The DSPE-PEG-biotin lipid conjugate co-localizes with lentiviruses ............. 42 
2.3  (E) Modified virus particles co-localize with streptavidin. ......................................... 43 
2.4  Lipid conjugates rapidly associate with retroviruses ............................................... 44 
2.5  Lipid conjugates stably associate with retroviruses ................................................. 45 
2.6  Retroviruses modified with the DSPE-PEG-biotin lipid conjugate bind to          
…….strepavidin-coated plates ............................................................................... 47 
 
CHAPTER 3  
3.1  The pathway of de novo sphingolipid biosynthesis and sites of action of myriocin, a 
serine palmitoyl-transferase inhibitor .............................................................................. 66 
3.2  (A) Mass spectroscopy analysis of ceramide present in virus producer cells ......... 67 
3.2  (B) Mass spectroscopy analysis of glucosylsphingolipid present in virus producer 
cells ................................................................................................................................. 68 
3.2  (C) Mass spectroscopy analysis of sphingomyelin present in virus producer cells.. 69 
3.2  (D) Mass spectroscopy analysis of ceramide present in virus particles................... 70 
3.2  (E) Mass spectroscopy analysis of glucosylsphingolipid present in virus particles ..71 
3.2  (F) Mass spectroscopy analysis of sphingomyelin present in virus particles ........... 72 
3.3  (A) Myriocin treatment does not affect virus production........................................... 74 
3.3  (B) Treatment of virus producer cells with ISP-1 decreases the titer of the virus 
produced from those cells  ............................................................................................. 75 
3.4  Effect of ISP-1 treatment on cell viability.................................................................. 76 
 ix 
3.5  (A) Myriocin treatment does not affect amount of gp70 incorporation into virus 
particles........................................................................................................................... 78 
3.5  (B) Myriocin treatment of virus producer cells does not affect structure of gp70 
incorporated into virus particles ...................................................................................... 79 
3.6  (A) Treating virus producer cells with ISP-1 does not decrease the amount of gp70 
incorporated into the virus particles.   ............................................................................ 80 
3.6  (B) Treating virus producer cells with ISP-1 does not decrease the amount of gp70 
incorporated into the virus particles ................................................................................ 81 
3.7  Stability of virus particles is not affected by myriocin treatment .............................. 82 
3.8  Binding of myriocin treated virus to target cells is not adversely affected ............... 84 
3.9  Virus particles produced by ISP-1 treated cells fuses less efficiently to target cells 
membrane ......................................................................................................................85 
3.10  (A) Mass spectroscopy analysis of ceramide present in target cell membrane 
before and after myriocin treatment ................................................................................ 86 
3.10  (B) Mass spectroscopy analysis of glucosylceramide present in target cell 
membrane before and after myriocin treatment .............................................................. 87 
3.10  (C) Mass spectroscopy analysis of sphingomyelin present in target cell membrane 
before and after myriocin treatment ................................................................................ 88 
3.11  (A) Treatment of NIH 3T3 cells with ISP-1 decreases virus infection..................... 90 
3.11  (B) Treatment of HeLa cells with ISP-1 decreases virus infection ......................... 91 
 
CHAPTER 4 
4.1  The pathway of de novo sphingolipid biosynthesis and sites of action of FB-1 ..... 109 
4.2  (A)  Mass spectroscopy analysis of ceramide present in virus producer cells ....... 110 
4.2  (B) Mass spectroscopy analysis of glucosylceramide present in virus producer cells .  
…………………………………………………………………………………………………..111 
4.2  (C) Mass spectroscopy analysis of sphingomyelin present in virus producer cells 
………………………...................................................................................................... 112 
4.2  (D) Mass spectroscopy analysis of ceramide present in virus particles ................. 113 
4.2  (E) Mass spectroscopy analysis of glucosylceramide present in virus particles ... 114 
4.2  (F) Mass spectroscopy analysis of sphingomyelin present in virus particles ........ 115 
4.3  Effect of varying doses of FB-1 treatment on cell viability ..................................... 117 
4.4  (A) Fumonisin treatment affects virus production................................................... 118 
4.4  (B) Effect of fumonisin treatment on gp70 production............................................ 119 
4.4  (C) Amount of gp70 proteins per p30 virus capsid protein ..................................... 120 
4.5  Fumonisin treatment affects the ability of virus to bud from target cell membranes ....  
…………………………………………………………………………………………………..121 
 x 
4.6  (A) Effect on virus production and infection after treating virus producer cells with 
FB-1 .............................................................................................................................. 123 
4.6  (B) Treatment of virus producer cells with FB-1 increases the titer of the virus 
produced from those cells ............................................................................................. 124 
4.7  Stability of virus particles is not affected by fumonisin treatment ........................... 125 
4.8  (A) Binding of virus particles to NIH 3T3 cells is not saturated at high concentrations 
of virus........................................................................................................................... 126 
4.8  (B) Binding of virus particles produced from myriocin treated virus producer cells is 
not adversely affected ................................................................................................... 128 
4.9  Virus particles produced by FB-1 treated cells fuse more efficiently with target cells ..  
…………………………………………………………………………………………………..129 
4.10 (A) Effect of virus infection after FB-1 treatment of NIH 3T3 cells......................... 130 







The most common gene transfer vehicle used in gene therapy protocols are 
mammalian virus vectors.  Specifically, retroviruses are one of the most common viral 
vectors used since they are able to permanently integrate their transgene into the host 
cell genome, providing, in principal, to a long-term cure.   The potential applications of 
gene therapies are vast, ranging from monogenic disorders such as cystic fibrosis to 
complex gene disorders such as cancer.  However, the application of such therapies in 
clinical settings has been limited partially because of inefficient gene delivery of the 
therapeutic gene to diseased cells.  Furthermore, safety concerns of accidently altering 
the genetic expression in healthy bystander cells or nearby tissue has increased the 
interest in creating targeted viral vectors which infect only the diseased cells without 
infecting others.  Thus, the success of gene therapy will depend on identifying and 
understanding the parameters critical for virus entry into cells, including factors that 
facilitate virus absorption onto the cell surface, virus binding, and fusion.   The objective 
of this thesis was to understand the role of lipids in binding and infection, and to 
investigate the use of lipid-based conjugates to alter the surface of virus particles.   
  
In this thesis, we described a novel method for modifying the surfaces of 
retrovirus particles using lipid conjugates.  We developed a method for rapidly modifying 
the surface properties of retroviruses using conjugates that are composed of a 
hydrophobic lipid anchor, 1,2-Distearoyl-sn-Glycero-3-phosphoethanolamine (DSPE), 
attached to a polymer linker, poly (ethylene glycol) chain which is covalently attached to 
the targeting functional group, biotin. These constructs, when mixed with a virus stock, 
rapidly associate with the virus surface. We used model replication-incompetent 
amphotropic retroviruses that encoded lacZ gene to investigate the characteristics of 
 xii 
lipid conjugate modification containing biotin as a model cell-targeting group.  We found 
that in less than 2 hours, the number of constructs that were associated with the 
particles reached a maximum. Even though the lipid conjugates were not covalently 
bound to the viruses, less than 30% dissociated from the viruses after 8 hours of 
incubation at 370 C in medium that contained 10% serum. Viruses modified with biotin 
conjugates bound to streptavidin-coated plates three-fold more than unmodified viruses.  
Importantly, virus titer experiments showed that the conjugates did not reduce the ability 
of the viruses to transduce cells.  The implication of this work for improving the 
characteristics of retroviruses in gene therapy and vaccination protocols is discussed.   
  
 In chapter 3 we investigated the use of fungal endotoxin, myriocin (ISP-1) to 
inhibit de novo sphingolipid synthesis in virus producer cells.  We investigated the effect 
on the lipid composition of the virus producing cells as well as the virus produced after 
treatment. Sphingolipids have been implicated in a variety of pathogens to help facilitate 
the entry process.   Here we studied the effect of altering the lipid composition of virus 
particles on virus function.  Our results suggest that the virus lipid composition can be 
significantly altered by treating cells with ISP-1 and that these particles exhibit reduced 
infectivity in a cell-type dependant manner.  Furthermore, the lipids of enveloped viruses 
play an important role in virus viral morphogenesis and infectivity, therefore we 
investigated different steps involved in the virus infection pathway and found that virus 
particles produced from ISP-1 treated cells are less fusogenic as compared to untreated 
cells.  The implications of these results to improve gene therapy vectors and anti-
retroviral therapies are discussed.   
  
 In chapter 4 we determined the effect of blocking sphingolipid synthesis by using 
fumonisin B-1 (FB-1) of virus producing cells and examined the effect on virus function.  
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We found culturing virus producer cells in the presence of FB-1 causes drastic decrease 
in the levels of ceramide, sphingomyelin and glucosyphingolipids.   Viruses produced 
with 50 µM FB-1 treatment were observed to be as stable as, and bind to the same 
extent as viruses produced from untreated cells.  Interestingly, virus from FB-1 treatment 
was 4 to 6-fold more infectious at doses of 100 µM than controls virus particles.  
Interestingly, we found that FB-1 treatment interferes with virus budding and release 











1.1 Gene Therapy 
 Gene therapy is an important approach to the treatment of diseases, which 
involves the delivery of genetic material into cells to produce a therapeutic effect.   Initial 
efforts in the 1970’s and 1980’s in developing recombinant DNA technologies were 
aimed at treating monogenic disorders, where a ‘normal’ gene was inserted into 
diseased cells to replace an ‘abnormal’ gene (17).  Since this time gene therapy has 
been expanded to a broad range of applications to include complex acquired genetic 
disorders such as cancer, infectious diseases such as human immunodeficiency virus 
(HIV) and has many applications in tissue and stem cell engineering (1, 2, 11, 12, 17).    
Currently almost 70% of the gene therapy clinical trials use viral vectors, in the hopes of 
exploiting the ability of viruses to efficiently infect and express their transgene in host 
cells (2, 22, 79).   Non-viral gene delivery methods, such as those involving delivery of 
plasmid DNA by mechanical or electrical stimulation or by complexing with charged 
polymers, are currently limited by low gene transfer efficiencies (61, 82).   Building on 
the advantage that viruses have had millions of years to evolve their ability to efficiently 
bind, fuse and infect cells, most research efforts have focused on identifying and 
overcoming major limitations with retroviral vectors.   
 Gene therapy can be clinically applied in two settings: ex vivo or in vivo.  In ex 
vivo gene therapy, cells are harvested from the patient, expanded outside of the body, 
genetically modified using a gene-delivery vector, then cells are cultured under selective 
pressure to obtain only the cells with the gene modification and finally, the cells are 
implanted back into the patient to elicit the desired therapeutic effect (2, 17).   Although 
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in this setting gene delivery occurs under controlled conditions and the vector can be 
targeted and optimized for gene transfer, this method is not always feasible.  Frequently, 
ex vivo gene therapy is not possible because the diseased cells/tissues cannot be 
excised from the patient, such as in diseases afflicting the heart, lungs or brain.  In these 
cases, in vivo gene therapy is used and the gene-delivery vector carrying the therapeutic 
gene is directly injected into the patient’s body (47, 84, 89).   For this method to be 
effective however, the viral vector should be specifically targeted to the cells of interest 
such that it does not genetically alter nearby healthy cells.   Clinical trials have 
highlighted some limitations with viral gene therapies and one main limitation has been 
the lack of transductional targeting, that is, the efficient delivery of genes to a desired cell 
type, without harming nearby bystander cells (3, 29, 79).   In either setting used for gene 
therapy, a targeted gene delivery vector would be advantageous because it would 
reduce the need to select and expand the targeted cell type in ex vivo protocols and 
provide a more suitable delivery vector for in vivo gene therapy.   
 To date there more than 1,000 gene therapy clinical trials have been completed, 
and one of the main obstacles has been the inability to control the retroviral tropism; that 
is, the types of cells that retroviruses can and cannot, transduce (37, 43, 87). In certain 
applications, virus tropism needs to be narrowed in order to deliver genes to only 
diseased cells without damaging surrounding tissue such as in the case of delivering 
apoptotic genes to cancer cells (2). In other applications, such as for cystic fibrosis, the 
retroviral tropism may need to be broadened such that the retroviruses can transduce 
the lung epithelial cells (14, 29). 
 
1.2 Recombinant Retroviruses as Gene Delivery Vectors 
 Retroviruses are the most common viral vector used for gene therapy protocols 
because they can permanently integrate a therapeutic gene into the DNA of target cells, 
 3 
resulting theoretically in a long-term cure (2, 16).   Specifically, Moloney murine leukemia 
viruses (MLV) are the class of retroviruses most often used for human gene transfer 
(43).  These retroviruses consist of two copies of genomic RNA packaged in a protein 
capsid, which is surrounded by a lipid bilayer composed of virus and host cell proteins 
and lipids (Table 1.1). This lipid envelope contains polypeptide chains including receptor 
binding proteins (i.e. envelope proteins) which interact with cell specific receptors and 
initiate the process of fusion and hence, infection.  The recombinant viral particles are 
structurally identical to the wild type virus but carry a genetically engineered genome that 
encodes for the therapeutic gene of interest.  These recombinant viruses are incapable 
of self-replication but can infect and insert their genomes into the cellular genome of a 
target cell (2).   
 Recombinant retroviruses can be manipulated altered in a number of ways.  For 
instance, wild type MLV virus particles consist of ecotropic envelope proteins that bind to 
the mouse cationic amino acid transporter -1 (mCAT-1) (28, 66).  Since this receptor is 
only found on rodent cells, infection of ecotropic MLV can only infect murine cells.  To 
make this vector clinically relevant for human cell lines, a different envelope protein is 
expressed in virus producing cells, in a process called pseudotyping (32, 38).  
Amphotropic retroviruses are of primary interest in human gene therapy protocols 
because they can infect human cells.  These proteins interact with cell surface receptors, 
sodium-dependant phosphate transporter protein (pit2), found on many different types of 
human cells (28).    Furthermore, lentivirus vectors are a subclass of retroviruses and 
have been pseudotyped with different envelope proteins for a wide range of applications 
(36, 78).   Lentiviruses are an interesting vector type also because they have an added 
benefit in that they can infect and integrate their genome into non-dividing cells (Table 
1.1) (8, 19, 32, 78).  In contrast to retroviruses, which can only infect dividing cells, 
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lentivirus vectors can be used for a broad range of applications to treat cells that have 
slow rates of division.   
 
1.3 Retrovirus Production 
 Recombinant retroviruses are similar to the wild-type virus from which they were 
derived, however they are engineered to encode therapeutic genes or other genes of 
interest, and do not contain viral genes necessary for replication (2, 48).    For the 
production of recombinant retroviruses, packaging cell lines are transfected with more 
than one plasmid encoding for viral proteins (gag, pol, env) and the therapeutic gene 
(Figure 1.1) (2, 51).  Gag encodes the capsid proteins and is necessary for 
encapsidation of the viral particle.  Pol encodes the enzymatic activities of the virus 
including reverse transcriptase. Env encodes the surface proteins that bind to cell 
surface receptors on the target cell.  Many times cell lines are stably transfected with the 
viral genes to create derivative cell lines that permanently produce virus particles in their 
cell culture medium.  For instance, for the studies conducted in this dissertation, we used 
a stably transfected cell line called Telceb6, derived from stable transfection of TE671 
cells (neuron-derived medulloblastoma human line) with the E.coli lacZ gene (without a 
nuclear localization sequence), MLV gag and pol genes and the amphotropic envelope 
glycoprotein (15, 45).   
 Transfection with these plasmids provides the packaging cell line with the genetic 
information needed to expresses all the structural viral genes necessary to form an 
infectious virus particle.  The therapeutic vector encodes the transgene(s) and the 
regulatory sequences necessary for their expression as well as a special packaging 
sequence (ψ) which is required for encapsidation of the genome into an infectious viral 
particle (51).  The structural proteins of the virus and the RNA genome self-assemble 
inside the transfected cell and bud from the plasma membrane of the cell into the culture 
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nm 90-147 110-128 (21, 68) 
Mass 
 
g 3.6 x 10-16 3.15 x 10-16 (30, 74) 
Genome size 
 
kb 8.3 9.2 (50, 74) 
Typical titers 
 
(units/mL) 108 106 (39, 54) 
Shape of capsid 
 
 Hexamer Conical (6, 49) 
Chromosomal integration 
 
 Yes Yes (36, 79) 
Infects quiescent cells 
 
 No Yes (32) 
Risk by activation of 
oncogene  
 ++ +  (3, 39, 65) 
     
Composition     
RNA 
 
% 2  (67) 
Protein  
 
% 62  (67) 
Lipid 
 
% 36  (67) 
 
 
HIV-1 Lipid Composition (7)                                                                




Phosphatidylcholine 26,000 9.0 
Sphingomyelin 37,000 13.0 
Dyhydrosphingomyelin 17,000 5.9 
Phosphatidylethanolamine 13,000 4.5 
Plasmogen Phosphatidylethanolamine  44,000 15.3 
Phosphatidylserine 25,000 8.7 
Cholesterol  134,000 46.7 
Ceramide 160 0.05 
Glucosylceramide 600 0.21 
 
 6 
media.  The conditioned medium, which contains infectious recombinant viruses, is 
harvested and used to transduce target cells. 
 
1.4 Retrovirus Infection  
 A retrovirus must complete several steps for the therapeutic gene to be 
successfully inserted into the genome of a target cell. First the virus must reach the cell 
surface by convection or diffusion where it attaches to components of the glycocalyx on 
the target cell surface (24).   Initially, the virus binds to the cell surface through 
nonspecific interactions between the proteins on the cell surface and on the virus (Figure 
1.2) (18, 57, 58).  These initial binding events between virus particles to the host cell 
membrane have been shown to occur by receptor – envelope independent interactions 
(4, 57).  For example recent studies by Pizzato et al found that virus particles bind to 
cells even when the cells did not express the virus receptor (57).  Furthermore, virus 
binding was observed even when envelope-defective virus particles were used, 
suggesting that the virus encoded envelope proteins do not control virus binding.  
Altogether, the results from these studies indicate that the initial interaction between 
virus particles and the cell surface is partially mediated by non envelope-receptor 
interactions.  Therefore current strategies used to target viruses by altering virus 
envelope proteins do little to mitigate receptor-envelope independent interactions  (4, 57, 
71, 88).      
 After the initial binding of virus particles to the cell surface, the virus envelope 
proteins (fusion proteins) bind to their cognate cell receptors (if present), bringing the two 
membranes in close apposition with each other (76).  This initial apposition forms a stalk 
or hemifusion intermediate which allows for fusion of the outer leaflets of the membranes 
(Figure 1.3).  At this stage, the outer leaflet of the virus and cell lipid bilayers are merged 
but the inner leaflets and the aqueous compartments, remain separate (83).   The virus 
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fusion proteins, which remain anchored within one bilayer, undergo conformational 
changes that reveal a hydrophobic fusion peptide (10, 83).  This peptide inserts into the 
apposed host cell membrane and oligomerizes, thus stressing the apposed bilayers 
causing the formation of a fusion pore (83).  This early pore formation enlarges to give 
rise to the late fusion pore, at which point the virus protein-RNA complex is released into 
the cytoplasm of the cell (25).  The naked RNA genome of the retrovirus is reverse 
transcribed into DNA by a virus associated enzyme (reverse transcriptase) and the 
protein-DNA complex is transported to the nucleus where it is integrated into the host 
cell genome by the virus associated enzyme integrase. During and after integration, the 
therapeutic gene is transcribed and translated to elicit the desired effect.   
 
1.5 Insertion Mutagenesis Concerns in Retrovirus and Lentivirus Vectors  
 In an ideal setting, a vector would integrate its genome into the host genome of 
long-term repopulating cells and express the ‘corrective’ gene for the life span of the 
infected cells as well as their progeny without significant toxic or immunogenic effects.  
However, gene therapy clinical trials worldwide have helped highlight many limitations 
still present with gene therapy vectors.  Using model systems, researchers have known 
for many years that onco-retroviruses have the potential to induce cancers (41, 44, 75).  
Cancer development requires a series of DNA changes which lead to disruption in cell 
division and apoptosis, hence it was believed that multiple retrovirus integration events 
in a cell evolve into tumorigenesis.    Interestingly, studies conducted with experimental 
tumors resulting from retrovirus infection suggest that oncogenesis is usually caused by 
only one insert (73).  Furthermore, two patients treated for X-linked severe combined 
immunodeficiency (X-SCID) in 2002 using retroviral gene therapy were diagnosed with 






















Figure 1.1 Production of recombinant retroviruses.  Recombinant retroviruses are 
produced by transfecting packaging cells with plasmids carrying the therapeutic vector 
and other plasmids encoding structural proteins of a retrovirus particle.  Viral proteins 
expressed from the viral vector self-assemble with the therapeutic gene near the cell 
membrane.  The therapeutic gene contains a packaging sequence (ψ) that allows for 
efficient incorporation of the therapeutic gene into the budding virus particles.   The 
assembled virus particle buds from the cell membrane, acquiring viral envelope proteins 
as well as host cell proteins in its lipid bilayer.   
 





































Figure 1.2 Transduction of target cells by recombinant retroviruses.   Retroviruses 
first diffuse to the cell and bind to the cell surface via nonspecific interactions.  The virus 
envelope proteins then bind irreversibly to specific cell receptors, initiating 
conformational changes that facilitate fusion between the virus lipid bilayer and the cell 
membrane.  After fusion, the internal components of the virus are released into the cell 
cytoplasm and the RNA genome is reverse transcribed to DNA.  This DNA is integrated 
into the host cell genome and now can be transcribed and translated to express the 






















 events have been linked to the aberrant expression of the same gene, LMO-2 locus, 
and therefore suggests that oncogenesis related with retroviral gene therapy is not 
random and may share a common mechanism.   For this reason many efforts have been 
made to predict the sites of integration preferred by viral vectors.   
 Many studies suggest that the site of viral vector integration is dependant on the 
virus vector used to deliver the gene.  Recent studies have revealed that the human 
immunodeficiency virus (HIV-1) integration occurs along the length of transcriptionally 
active genes (46, 69).  Several HIV-1 hotspots have been identified, including a 2.5 kb 
region which contained nearly 1% of the integration events.  The Moloney murine 
leukemia virus (MLV) integration events however, have been shown to largely occur 
near transcription start regions and CpG islands (54).  Specifically, 17% of the MLV-
vector integration was near transcription start regions and another 17% was seen to 
occur near CpG islands (86).  This preference for retrovirus vector insertion near 
transcriptionally active genes may directly affect nearby gene enhancer and promoter 
regions, thereby influencing gene expression.  Also, vector promoter may itself give rise 
to functional gene transcript, thereby giving rise to a full-length functional gene transcript.  
Thus, because of the preference retrovirus vectors exhibit to integrate their genes near 
promoters or transcriptionally active genes, they are thought to be more prone to 
inducing insertional mutagenesis than lentivirus vectors (77).   
 
1.6 Lipid Composition of Virus Particles 
 Interestingly, recent studies suggest that retrovirus binding is controlled by 
factors other than their viral envelope proteins and that these proteins are not, as 
previously thought, required for virus binding, but are primarily for mediating fusion and 
entry of the virus particle after it binds to the cell. Research studies on the lipid 
composition of the retroviral bilayer revealed that the proteins responsible for mediating 
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viral fusion are derived from specific sites within the plasma membrane of virus 
producing cells, called lipid rafts (42). Lipid rafts are specialized membrane domains 
enriched in certain lipids, mainly cholesterol (CH), and sphingolipids.  More recently, it 
was shown that retroviral membranes contain dihydrosphingomyelin (DHSM), an 
uncommon subspecies of SM (7, 59). These researchers showed that inhibition of the 
DHSM backbone significantly reduces HIV-1 infectivity and provided proof of concept 
that particular subcategories of lipids can be viewed as targets for the modulation of 
retroviral infection (59, 81).  These discoveries suggest that a comprehensive 
understanding of the role of lipids in retrovirus production and infectivity is necessary for 
the successful construction of an effective targeted retrovirus for gene therapy.  
 Furthermore, lipids and proteins on the surface of enveloped viruses are known 
to play a key role in the infection of host cells by inducing fusion of the viral and target 
cell membrane (59, 80).  For efficient fusion of virus particles to the target cell, both the 
virus envelope proteins and lipid constituents in the viral lipid bilayer must work 
cooperatively (59).  It is known that lipids within the viral membrane are not incorporated 
randomly, and are heavily enriched in cholesterol (CH), sphingolipids (SL), 
sphingomyelin (SM) and glycolipids, possibly because retroviruses bud from specialized 
sites within the plasma membrane, called lipid rafts (Table 1.1, Figure 1.4) (53).  It is 
suggested that viruses acquire signaling proteins and lipids during the budding process 
and that these proteins and lipids play a significant role in virus attachment, fusion and 
entry (9).    
 Interestingly, recent studies show that, indeed, altering the lipid composition of 
virus particles or the target cell membrane significantly reduces the ability of the viruses 
to infect cells (7, 63).  Recently, several studies have demonstrated that depletion of 
lipids from the target cell inhibits virus fusion and subsequent infection (26, 27).  
Furthermore, Hug et al found that blocking the sphingolipid (SL) biosynthesis in cells 
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reduced their susceptibility for retrovirus infection, thus implying that retroviruses utilize 
SL in their fusion process.  Interestingly, reconstituting the SL restored virus fusion and 
its subsequent infection. Therefore, modulating lipid content of virus particles or viral 
producer cells can have critical implications in altering the viral fusion properties.  It is 
also important to note that not all enveloped viruses have specific lipid requirements 
(such as influenza virus) probably because these viruses enter host cells through pH-
dependant pathway and thus have a considerably different mechanism of entry into the 
host cell (76).  The most recent studies show that viruses that use the cell membrane as 
platforms to gain entry are most affected by lipid composition, possibly because lipids 
are involved in the physicochemical and mechanical properties of the virus and host 
membrane as they relate to fusion (25, 76).   
 
1.7 Approaches to Retrovirus Targeting 
 Clinical trials have helped to highlight some major limitations of in vivo gene 
therapy.  One such limitation is the inability to transfer genes to a specific targeted cell 
type without affecting the surrounding non-targeted cells.  The types of cells a virus can 
infect is dictated in large part by its envelope proteins.  Many viral vectors commonly 
used for gene therapy are pseudotyped with the amphotropic envelope protein (17, 43).  
Amphotropic envelope proteins specifically interact with pit2 on the cell surface to 
facilitate infection (33, 66).   This protein is  found on many different types of cells in the 
human body, and therefore amphotropic viruses are not useful for transferring genes to 
a single targeted cell type or tissue (65).   Therefore, to achieve targeted gene transfer to 
diseased cells there is a need to narrow the tropism of virus vectors.   
 Most attempts to develop targeted viral vectors have for the most part focused on 




















Figure 1.3 Fusion between virus and cell lipid membrane is mediated by viral 
fusion proteins (Adapted from Harrison et al 2008).  Schematic of virus fusion pathway.  
Virus and cell membranes initially come into close apposition that leads to irreversible 
binding between virus fusion membranes and their cognate cell receptors (not shown).  
The virus fusion protein undergoes conformational changes, facilitating first the fusion of 
the outer leaflets of the membranes, then subsequently the inner leaflets.  The mixing of 
the inner lipid leaflets gives rise to the formation of the early fusion pore, which enlarges 
to form the late fusion pore.  At that stage, the viral protein-RNA capsid is delivered to 
the cell cytoplasm.    
Early fusion pore Hemifusion
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 their cognate cell surface receptors (Table 1.2).  It has been thought that since the 
interaction between viral envelope proteins and its cognate receptor is absolutely 
required for virus infection to occur, changing the properties of these proteins would alter 
virus infection (55, 72).  Perhaps the most common approach taken to alter the types of 
cells a virus binds to is by pseudotyping (i.e. replacing the viral envelope proteins with 
envelope proteins from another virus) (32, 38).   The tropism of most viruses is relatively 
broad however, and so this strategy does not allow specific targeting of viruses to one 
desired cell type (22, 32).   
 Therefore, to create targeted viruses, most efforts have focused on modifying the 
structure of the viral envelope proteins, either chemically or genetically, to enable them 
to bind to receptors that are expressed only by the cell type that is being targeted and no 
others (22).  Initial strategies to construct targeted virus vectors involved genetic 
incorporation of sequences for cell-specific ligands into the native virus envelope protein 
to enable virus binding to specific cell types (23, 40, 60).  Although these methods 
increased specific binding of the targeted virus, the altered envelope proteins lacked full 
activity (3, 79).   In a recent study, Qi et al showed that insertion of the PreS1 domain 
(108 amino acids in length) from hepatitis B virus envelope protein, into the receptor 
binding domain of the murine leukemia virus envelope (MLV) causes defects in protein 
processing of the chimeric envelope protein and results in inactive virus particles (60).   
Interestingly, virus particles constructed from inserting a small segment of the PreS1 
domain (26 amino acids) into their envelope protein sequence selectively bound and 
infected target cells (60).  Additionally, a systematic approach to examine the effect of 

























































that even insertion of short peptide ligands (such as the RGD peptide, 6 amino acids in 
length) had deleterious affects on virus infectivity.  Furthermore, the insertion of the 
peptides was shown to depend on the location of ligand insertion, size of the ligand, and 
the sequences flanking the ligand (23, 85).     Therefore, genetic engineering based 
strategies take time to develop, provide variable results and often fail to produce 
targeted viral vectors.    
  In an alternate approach, virus surfaces can be modified by covalently linking 
virus envelope proteins to binding motifs such as cell-specific growth factors, biotin-
streptavidin complexes, or targeting ligands attached to polymers chains for targeted cell 
transduction (79).   For instance, Reddy chemically conjugated activated folic acid to the 
surface of ecotropic retroviruses (64).  These studies indicated that the chemical 
conjugation process reduced virus infectivity by 3-fold.  In addition, when the same 
strategy was used to chemically conjugate folic acid on the surface of amphotropic 
adenoviruses, it was found that again, modified virus was significantly less efficient in 
transducing the folate expressing KB cells (64).  Data from this study and previous other 
studies implies that covalent modification of virus envelope proteins compromise the 
ability of envelope proteins to initiate fusion by inhibiting post-binding conformational 
changes necessary for membrane fusion (78, 88).   
 Interestingly, researchers have attempted to use small molecules that did not 
interfere with virus envelope structure and function, and have shown that virus binding 
and infection can be successfully redirected towards a desired cell-type (52).  Neda et al 
chemically coupled lactose (360 MW) residues to the surface of ecotropic retroviruses 
and showed that the modified virus could efficiently bind and transduce human 
hepatocytes via the asialoglycoprotein receptor (52).   Although, the results from this 
study indicate that envelope proteins have some tolerance 
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for covalent attachment of ligands, there have been limited successes applying this 
strategy to target infection to other cell-types (35, 79).  Altogether, covalent modification 
strategies engineer the virus envelope protein with the intention that virus binding and 
fusion will be triggered by the interaction between displayed targeting ligand and its 
cognate cell receptor, however most of the time, these modifications have deleterious 
effects on envelope protein function (78, 79).    
   
1.8 Thesis Objectives 
 The overall objective of this thesis was to determine the effect of modifying the 
composition of viral lipid bilayer on retrovirus transduction.  To accomplish these 
objectives we pursued the following aims:  
1. Determine if lipid conjugates can be used to alter the lipid bilayer of 
retrovirus particles. We hypothesize that the surface of retrovirus particles 
can be non-covalently modified using lipid-polyethyleneglycol (PEG) 
conjugates to increase virus binding to a targeted receptor without adversely 
altering the function of native viral envelope proteins.  
2. Investigate the extent to which altering the lipid composition of the 
bilayer of retroviruses affects their ability to transduce cells.  We 
hypothesize that treating virus producer cells with a lipid inhibitor will 
decrease sphingolipid levels in the virus lipid bilayer and affect the virus’ 
ability to transduce cells.    
3. Examine the mechanism by which changes in the lipid composition of 
retrovirus bilayers affects their ability to transduce cells.  We 
hypothesize that lipid inhibitors affect the fusiogenicity of the virus particles 
produced from treated cells.    
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1.9 Organization of the Thesis 
 In chapter 1 we provide an overview of gene therapy and specifically the use of 
recombinant retroviruses in gene therapy protocols.  We discuss the main approaches 
taken to construct targeted retroviral vectors and also, the role that lipids play in virus 
targeting.   We also discuss the motivation and significance of the thesis project.   We 
identify some of the main limitations with current gene transfer methods and discuss the 
goals we have formulated to address them.   
 In chapter 2, we examine a new method for rapidly modifying retroviruses by 
using lipid conjugates composed of a lipid anchor, a polymer chain and a targeting 
moiety.  We characterize the rate of adsorption and desorption of the lipid conjugate to 
the virus surface, and the affect of this modification on virus binding.  Finally, we test the 
ability of the modified viruses to infect cells.   
 In chapter 3, we alter the lipid composition of retrovirus particles by using the 
fungal endotoxin, myriocin, to inhibit serine palmitoyltransferase in the de novo 
sphingolipid pathway of the virus producer cells.  We characterize the changes in lipid 
composition of the virus membrane, examine the affect of these changes on virus 
infectivity, and determine if changes in the transduction efficiency of the altered virus 
particles is cell-type dependant.   
 In chapter 4, we examine the mechanism by which changes in the lipid 
composition, caused by treatment of virus producer cells with endotoxin, fumonisin B-1, 
affects virus infection.  We examine the effect of fumonisin B-1 treatment of virus 
producer cells on the rate of virus production, the incorporation of viral envelope proteins 
into the viruses they produce, and the ability of these viruses to bind and fuse with cells.   
 In chapter 5, we summarize our major conclusions and present some 
suggestions for future work.   
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1.10 Outcome & Contribution 
 One outcome of these studies has been the establishment of a rapid and flexible 
method for modifying the surfaces of retroviruses. The approach taken is fundamentally 
different from previous virus modification methods because it employs a novel lipid-
polymer targeting strategy that non-covalently modifies the virus surface without altering 
virus infectivity, and because it has the potential to block non-receptor mediated binding 
of retroviruses to cells.   Furthermore we manipulated the lipid content of retroviruses 
and examined the effect on virus binding, fusion and infection.  The results of these 
studies helped elucidate the role of viral lipids in infection and provided insights into how 
the lipid content of viral vectors might be manipulated in the future to improve their 
function for use in human gene therapy protocols.  Finally, the concept of virus targeting 
using the lipid-polymer method may have potentially broad reaching applications in virus 
detection, diagnosis and vaccine construction.   This work is significant because 1) it 
utilizes a novel lipid-polymer targeting strategy that confers upon retroviruses the ability 
to bind to specific receptors while maintaining their ability to efficiently transfer genes to 
cells, and 2) attempts to control the lipid composition of retroviruses as a means to alter 
the selectivity of their fusogenicity, which has been the major challenge in previous virus 
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RAPID MODIFICATION OF RETROVIRUSES USING LIPID CONJUGATES 
 
2.1 Abstract 
Methods are needed to manipulate natural nanoparticles.   Viruses are 
particularly interesting because they can act as therapeutic cellular delivery agents.  
Here we examine a new method for rapidly modifying retroviruses that uses lipid 
conjugates composed of a lipid anchor (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine), a polyethylene glycol chain, and biotin.  The conjugates rapidly 
and stably modified retroviruses and enabled them to bind streptavidin.   The implication 
of this work for modifying viruses for gene therapy and vaccination protocols is 
discussed.   
 
2.2 Introduction 
 As the use of nanostructures in a wide range of fields grows, the development of 
methods by which nanoparticles of natural origin (e.g. viruses) can be manipulated is 
becoming increasingly important (43, 49, 51). For example, the range of jobs for which 
viruses have evolved (carrying cargo, cell binding and entry, gene delivery) makes such 
natural nanoparticles intrinsically interesting for cellular delivery applications. 
Specifically, there is significant interest in engineering recombinant enveloped viruses 
that bind to a specific targeted cell type for gene therapy and vaccine applications (8, 17, 
29).  Strategies to develop targeted viral vectors have for the most part focused on 
controlling or altering the interactions between the envelope proteins of the viruses and 
their cognate cell surface receptors, since these interactions are absolutely required for 
virus infection to occur (33, 45).  Perhaps the most common approach taken to alter the 
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types of cells a virus binds to is to replace its envelope proteins with envelope proteins 
from another virus in a process called ‘pseudotyping’ (23, 35).  The cell types that a virus 
is able to infect (that is, its tropism) is dictated in large part by its envelope proteins, so 
pseudotyping viruses with envelope proteins from a different virus can significantly 
change, and potentially enhance the infectivity of the virus with respect to certain cells 
(17, 23).  Unfortunately the tropism of most pseudotyped viruses is relatively broad and 
rarely directly corresponds with what is required for targeted gene delivery (48).  
As a result, most efforts to create targeted viruses have focused on chemically or 
genetically altering the viral envelope proteins to include a binding motif for the targeted 
receptor (17).  Early studies frequently modified the ecotropic envelope protein because 
human cells do not express the ecotropic receptor.  The hypothesis central to this 
approach was that viruses pseudotyped with modified ecotropic envelope proteins would 
only be able to bind to and fuse with human cells that expressed the targeted receptor.  
There were some notable early successes using this approach.  For example, 
retroviruses pseudotyped with ecotropic envelope proteins that were genetically modified 
to contain erythropoietin were able to infect human cells bearing the erythropoietin 
receptor (24), and ecotropic retroviruses chemically modified with galactose were able to 
infect human HepG2 cells via the asialoglycoprotein receptor (32).  Unfortunately, this 
approach has proven difficult to generalize, primarily because the modified envelope 
proteins are usually not able to initiate fusion of the virus via interactions with the 
targeted receptor (52).  Viral envelope proteins, in general, must interact with their 
cognate cellular receptors in order to induce fusion, because binding to these receptors 
triggers cross-talk between the envelope glycoproteins and a series of conformational 
changes that are required to promote virus-cell fusion (47).   
Recently, alternative approaches have been explored that do not directly alter the 
structure of the viral envelope protein.  In one such approach, Snitkovsky et al. created 
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an adaptor protein, composed of the extracellular domain of the avian sarcoma and 
leukemia virus (ASLV) receptor and heregulin-β1, that served as a bridge between ASLV 
pseudotyped retroviruses and cells that expressed heregulin receptors (44).  A key 
advantage of this approach is that it does not require changes to the structure of the 
retroviral envelope protein, changes that often impair virus production or function.  Most 
adaptors tested to date, however, bind to the retroviral envelope proteins (39, 44), which 
often ablates the native tropism of the virus, and redirects the virus towards the targeted 
receptor.  A drawback of this approach is that adaptor – envelope protein pairs must be 
identified that will not only bind to the targeted receptor, but that also promote the 
conformational changes necessary to induce virus fusion (15).  It is not yet clear if this 
approach can be generalized to the targeting of other types of receptors or how readily it 
can be used with other retroviral envelope proteins. 
These previous studies showed that it is difficult to target retroviruses by 
manipulating their retroviral envelope proteins and prompted us to consider an 
alternative approach. In particular, the variety of “plug-and-play” self-assembled 
monolayer methods for the non-covalent modification of inorganic nanoparticles was 
extremely attractive; such self-assembly approaches permit rapid, non-covalent, and 
reconfigurable modification of the nanoparticle surface with a wide range of potential 
functionalities (2, 4, 13, 38). We postulated that the problem of enveloped virus particle 
modification could be solved if cell-specific binding motifs could be attached to viruses 
non-covalently, and without altering or otherwise influencing the structure and function of 
their envelope proteins. The obvious locus for such self-assembly is the lipid bilayers of 
such viruses, which should permit dynamic exchange between lipids in the envelope and 
those in the surrounding medium.  Replacement of native envelope lipids with ones 
presenting the desired functionality would thereby result in a semi-synthetic, self-
assembled virus coat  An approach similar to this has been used to target mammalian 
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cells to specific binding sites.  Dennis et al. showed that chrondrogenic progenitor cells, 
coated with lipidated protein G and bound to antibodies specific for cartilage matrix 
proteins, were able to home to the site of injured cartilage (12).  The lipidated protein G 
efficiently (in 2 hours at 37 °C) intercalated into the cellular lipid bilayer thereby providing 
an anchor for the targeting antibody.   Similar approaches are also common in the 
creation of targeted liposomes.  For example, Saul et al. incorporated lipid-PEG-folate 
conjugates into liposomes, and showed that the folate-modified liposomes were 
preferentially taken up by C6 glioma cells that expressed high levels of the folate 
receptor as compared to terminally differentiated primary cortical neurons derived from 
chick embryos, which do not express the folate receptor (41).   
Based on these findings with cells and liposomes, we hypothesized that lipid 
conjugates could be used to modify the surfaces of retroviruses without altering or 
compromising the structure or function of their envelope proteins.  To test this strategy, 
we modified the surfaces of amphotropic murine leukemia retroviruses with lipid 
conjugates composed of a double chain saturated lipid, a polyethylene glycol chain, and 
a biotin molecule. We then measured the effect of the modification on their infectivity, 
and examined their ability to bind to streptavidin, the native protein binding partner of 
biotin. The results of these studies clearly show the potential power of this approach, 
which should enable a versatile toolbox for non-covalent viral nanoparticle modification. 
 
2.3 Materials and Methods 
 Chemicals and Antibodies.  The lipid conjugate, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotinyl(polyethylene glycol)2000] (DSPE-PEG2000-biotin), was 
obtained from Avanti Polar Lipids (Alabaster, AL).  Rhodamine redTM-streptavidin was 
from Molecular Probes (Eugene OR).  Gluteraldehyde, and 1,5-dimethyl-1,5-
diazaundecamethylene polymethobromide (Polybrene, PB) were from Sigma Chemical 
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Co. (St. Louis, MO). Hydrogen peroxide 30%, and polyoxyethylene 20-sorbitan 
monolaurate (Tween 20) were from Fisher Scientific (Fair Lawn, NJ). Non-fat dry milk 
(blotting grade) was from Bio-Rad Laboratories (Hercules, CA). o-phenylenediamine 
dihydrochloride (OPD) was from Pierce (Rockford, IL). 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal) was from Denville Scientific, Inc. (Metuchen, NJ). Mouse anti-
p30 was purified from the supernatant of the CRL-1219 (ATCC, Rockville, MD) 
hybridoma cell lines following standard procedures (18). The biotin ELISA was from MD 
Biosciences (St. Paul, MN).   Poly-L-lysine was purchased from Sigma (St. Louis, MO). 
 Cell Culture.  HeLa cells (human cervical kidney) and 293T/17 cells (human 
embryonic kidney epithelial) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM; Hyclone Labs Inc., Logan, UT) with 10% fetal bovine serum (FBS; Hyclone 
Labs Inc.), 100 U/mL of penicillin and 100 µg/mL of streptomycin (Hyclone Labs Inc.).  
TELCeB6-A (TE671 cells stably transfected to express lacZ, Mo-MLVgagpol (28) and 
the amphotropic envelope glycoprotein (26)) were cultured in DMEM, 10% fetal bovine 
serum (Hyclone Labs, Inc.), 100 U/mL of penicillin, and 100 mg/mL of streptomycin 
(DMEM/FBS).   
 Virus Production.  To generate retrovirus stocks, TELCeB6-A cells were grown 
to confluence in T175 tissue culture flasks, and then incubated for 24 h with 30 mL of 
cell culture medium (26). The virus-laden tissue culture medium was harvested, filter 
sterilized (0.45 µm), then frozen (80 °C) for later use.  To produce lentivirus pseudotyped 
with the amphotropic envelope protein,  293 cells were plated in 12-well plates coated 
with poly-L-lysine (2 x 106 per well), then cotransfected the next day with a mixture of 
Lipofectamine 2000 (Invitrogen; Carlsbad, CA) , 8 µg of the packaging construct 
pCMV∆R8.91 (9), 8 µg of lentivirus vector pTYEFnlacZ (AIDS Research and Reference 
Reagent Program, Bethesda, MD), and 8 µg of the amphotropic envelope protein 
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expression plasmid pFB4070ASALF (53). Virus supernatants were harvested after 36 h, 
filter sterilized (0.45 µm), and frozen (-80 °C) for later use.   
 Retrovirus Modification.  Amphotropic retrovirus produced from TELCEB6-2A 
was pelleted using overnight centrifugation at 4 °C at 6000 × g, then concentrated 10-
fold by resuspending them in 1/10th their original volume in tris buffered saline (TBS) that 
contained 6 µg/mL solution of DSPE-PEG(2000)-biotin.  Samples were gently agitated 
on a rotating platform for 2 h at 4 °C, and then brought to 320 µg/mL of PB.  The 
resulting solution was incubated for 30 min at 37 °C, centrifuged at 10,000 × g for 20 
min, and then the pellet resuspended to the original volume with TBS and analyzed 
using an enzyme-linked immunosorbent assay (ELISA) for p30 and biotin.   
 ELISA for p30 and Biotin.  The concentration of virus capsid protein (p30) was 
quantified using a previously described enzyme-linked immunosorbent assay (ELISA) 
(26). Briefly, ELISA plates (Nunc immuno Maxisorp 96-well plates, Nalgen Nunc 
International, Rochester, NY) were coated overnight at 4 °C with 10 µg/mL of mouse 
anti-p30 antibody (100 µL/well) in PBS. The next day, the antibody solution was 
removed and blocking buffer (PBS, 0.05% Tween-20, 5% non-fat milk) added (200 
µL/well) for 2 h at 37°C to block non-specific binding sites. Virus particles were lysed 
using 0.5% Triton-X to expose the p30 antigen, then added to the ELISA plate (100 
µL/well) and incubated for 1 h at 37 °C. Bound p30 was sandwiched by the addition of 
the goat polyclonal anti-p30 antibody for 1 h at 37 °C (26). The horseradish peroxidase 
conjugated polyclonal rabbit anti-goat immunoglobulin G was then added in blocking 
buffer to the ELISA plate (100 µL/well) for 1 h at 37 °C to enable detection and 
quantitation of the sandwiched p30 antigen. The plates were developed for 5 min using 
hydrogen peroxide (H2O2) and OPD (100 µg/well) from a solution of 3 mg of OPD and 3 
µl H2O2 in 7.5 mL of substrate buffer (24 mM citric acid-monohydrate, 51 mM Na2HPO4-
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7H20, pH 5.0).  Sulfuric acid (8 N, 50 µL/well) was used to stop the reaction, the optical 
density at 490 nm was  measured using an absorbance plate reader, and the non-
specific background at 650 nm was subtracted. Values for replicate wells without virus 
were subtracted as background. 
 To quantify biotin levels, we used a commercially available ELISA kit according 
to the manufacturer’s instructions (MD Biosciences).  Briefly, samples were incubated on 
streptavidin coated plates for 30 min at room temperature.   The wells were then 
incubated with enzyme-labeled biotin for 30 min, washed, and developed using the 
manufacturer’s substrate (urea peroxide) and chromogen (tetramethylbenzidine).  The 
plates were developed for 30 min.  Sulfuric acid (2 N) was used to stop the reaction and 
the optical density at 450 nm measured using an absorbance plate reader. Values for 
replicate wells without virus were subtracted as background.   
 Fluorescence Microscopy Co-localization Assay.  To determine if the lipid 
conjugates were directly associated with the virus particles, we modified GFP-labeled 
lentiviruses with DSPE-PEG2000-biotin and then subsequently labeled them with 
rhodamine-streptavidin.   The lentivirus was first concentrated 10-fold using overnight 
centrifugation at 4 °C at 6000 × g.  Then it was resuspended in a 6 µg/mL solution of 
DSPE-PEG(2000)-biotin in TBS or in TBS alone (control).  After agitation on a rotating 
platform (2 h, 4 °C), a small aliquot of the solution was mixed at 1:1 ratio of 10 µg/mL 
rhodamine-streptavidin.   After labeling for 5 min at 37 °C, 10µl of the mixture was 
visualized by epifluorescence microscopy using the 60 x lens of an inverted microscope 
(Olympus IX50; Melville, NY).   As a control GFP-labeled lentivirus was not reacted with 
functionalized PEG lipid but allowed to incubate with rhodamine-streptavidin.  The 
number of GFP-labeled virus particles co-localized with rhodamine-streptavidin and the 
number of GFP-labeled virus particles alone were counted and averaged over ten 
random fields of view.   
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 Measurement of Lipid Conjugate Association and Dissociation Rates.  To 
determine the rate at which DSPE-PEG2000-biotin modifies retrovirus, frozen lacZ virus 
stocks in culture medium were thawed, centrifuged (6000 × g, 4 °C) overnight, after 
which the pelleted virus was modified with DSPE-PEG2000-biotin or, as a control, mock-
modified with TBS only.  Samples were incubated at 37 °C or 4 °C.  At intervals (after 
0.5, 1, 2, and 5 h) virus particles were separated from unbound DSPE-PEG2000-biotin by 
flocculation with Polybrene (320 µg/mL) for 30 min at 37 °C, the flocculated virus 
pelleted by (10,000 × g, 20 min), the pelleted virus resuspended in TBS to its original 
volume, and analyzed for p30 and biotin content by ELISA. 
 To determine the rate at which DSPE-PEG2000-biotin dissociates from retrovirus,    
retrovirus (100 µL) was brought to 6 µg/mL of DSPE-PEG-biotin, incubated 2 h at 4 °C, 
flocculated with Polybrene (320 µg/mL) for 30 min at 37 °C, pelleted by centrifugation 
(10,000 × g, 30 min), resuspended in 100 µL of TBS, or TBS with 10% fetal bovine 
serum, and incubated for 8 hours at 37 °C or 4 °C.   Next, the retroviruses were 
flocculated with Polybrene (320 µg/mL) for 30 min at 37 °C and pelleted by 
centrifugation (10,000 × g, 30 min) to separate them from newly dissociated DSPE-
PEG2000-biotin, and then resuspended to their original volume in TBS and the amount of 
DSPE-PEG-biotin still associated with them quantified by ELISA.   
 Streptavidin Binding Assay.  To examine the effect of the lipid conjugates on 
the ability of the viruses to bind to streptavidin, amphotropic virus stocks were 
concentrated 10-fold by centrifuging (6000 × g, 4 °C) them overnight and then 
resuspending the pelleted virus in TBS to  1/10th their original volume.   The 
concentrated virus was incubated (2 h, 4 °C) with DSPE-PEG2000-biotin (6 µg/mL) in 
TBS.  The virus particles, now modified DSPE-PEG2000-biotin, were separated from 
unbound DSPE-PEG2000-biotin by flocculation with Polybrene (320 µg/mL) for 30 min at 
 36 
37 °C, the flocculated virus pelleted by (10,000 × g, 20 min), the pelleted virus 
resuspended in NaCl (1 M) and applied to a streptavidin coated plate.  A small aliquot of 
each sample was taken, before it was applied to the coated plate, and the amount of p30 
quantified by ELISA.  To accelerate virus binding, the plate was centrifuged (3000 × g) 
for 30 min at room temperature.  The wells were then washed (3 times, 200 µL) with the 
biotin ELISA wash buffer (10 mM PBS salt, pH7.4 and tween 20; MD Bioscience) to 
remove unbound virus.  To quantify the amount of bound virus, the wells were incubated 
(30 min at 37 °C) with lysis buffer (100 µl)  and the amount of p30 in the lysis buffer 
quantified by ELISA.  The amount of p30 that bound to the wells, as a fraction of the total 
amount that was added to the wells, was calculated.  
 Diluted Titer Assay.  Ten-fold serial dilutions of lacZ virus stock were made in 
DMEM/BCS and Polybrene (8 µg/mL). A 1-mL amount per well was used to transduce 
HeLa cells that had been seeded (8 x 104 per well) the previous day in a 12-well plate. 
Two days after the start of the transduction, the cells were fixed and stained for β-
galactosidase activity with X-Gal. Colonies of lacZ+ cells (typically in clusters of 2, 4, or 8 
blue cells) were counted with the aid of a dissecting microscope. At appropriate dilutions 
of the virus stock, the clusters of blue cells were sufficiently spread over the dish such 
that each cluster arose from a single transduction event. From triplicate wells, the 
number of lacZ+ CFU per milliliter of virus produced from TELCeB6-A cell line was 
approximately 2.5 ± 0.1 x 106.  The titer of the virus after it was modified with DSPE-
PEG2000-biotin was 5.6 ± 0.4 x 106 CFU/mL.   
 Statistical Analysis.  Data are summarized as the mean ± one standard 
deviation for triplicate samples.  Statistical analysis was performed using one-way 
analysis of variance for repeated measurements of the same variable.  The Tukey 
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multiple comparison test was used to conduct pairwise comparisons between means. 
Differences at p < 0.05 were considered statistically significant. 
 
2.4 Results  
As a first step to determine if lipid conjugates can modify the surfaces of 
retroviruses, we incubated (2 h, 4 °C) lacZ amphotropic retrovirus with DSPE-PEG-biotin 
(6 µg/mL, Figure 2.1).  Next, to separate the retroviruses from unincorporated lipid 
conjugate, we flocculated them with Polybrene (PB; 320 µg/mL), pelleted the resultant 
flocs of virus by low speed centrifugation (4 °C, 30 min, 10,000 x g), and then 
resuspended them to their original volume in tris-buffered saline (TBS).  As a control, we 
processed lipid conjugate solutions that did not contain any virus using the same 
procedure.  The amount of virus (i.e., virus capsid protein, p30) and biotin in the samples 
were quantified by ELISA.  As expected, we found that most of the virus particles (about 
80%) were in the pellet (Figure 2.2A).  Significant amounts of biotin were detected in the 
pellet, but only when virus particles were present in the sample (Figure 2.2B), which 
suggests that the lipid conjugates were physically associated with the virus particles.  
To determine if the lipid conjugates were directly associated with the retrovirus 
particles, we incubated (2 h, 4 °C) stocks of GFP-labeled amphotropic lentivirus with 
DSPE-PEG-biotin (6 µg/mL), or in TBS as a control, added rhodamine-streptavidin (10 
mM) to the stocks, and then visualized the samples by epifluoresence microcopy (Figure 
2.3 A-D).  Several random fields of view were observed, and the fraction of viruses that 
were colocalized with the red fluorophore (rhodamine) was determined (Figure 2.3 E).  
Most of the GFP-labeled viruses co-localized with rhodamine (94% ± 4%), which 
suggests that the lipid conjugates directly associate with, and physically modify the 


























Figure 2.1 Structure of the DSPE-PEG-biotin (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotinyl(polyethylene glycol)2000]) lipid conjugate used to 
































Figure 2.2 (A).  The DSPE-PEG-biotin lipid conjugate co-purifies with retroviruses.  
Retrovirus stock (100 µL), or tris buffered saline (TBS) as a control, was brought to 6 
µg/mL of DSPE-PEG-biotin, incubated for 2 h at 4 °C, and then flocculated with 
Polybrene (320 µg/mL) for 30 min at 37 °C.  The flocculated virus was pelleted by 
centrifugation (10,000 × g, 30 min), the supernatant decanted, and the pelleted virus 
resuspended to its original volume (100 µL) in TBS.  The concentration of (a) virus 
capsid protein (p30) in the original virus stock (NEAT), resuspended pellet (Pellet), and 
the decanted supernatant (SN) was quantified using an ELISA for p30.  Statistically 
significant differences (p < 0.05) from the original virus stock (NEAT) are denoted with 









































































Figure 2.2 (B).  The DSPE-PEG-biotin lipid conjugate co-purifies with retroviruses.  
Retrovirus stock (100 µL), or tris buffered saline (TBS) as a control, was brought to 6 
µg/mL of DSPE-PEG-biotin, incubated for 2 h at 4 °C, and then flocculated with 
Polybrene (320 µg/mL) for 30 min at 37 °C.  The flocculated virus was pelleted by 
centrifugation (10,000 × g, 30 min), the supernatant decanted, and the pelleted virus 
resuspended to its original volume (100 µL) in TBS.  The concentration of (b) biotin in 
the resuspended virus pellet (VL) and control pellet (L) was quantified using an ELISA 
for biotin. Statistically significant differences (p < 0.05) from the control pellet (L) are 
denoted with an asterisk.  Each point shows the mean and standard deviation of at least 





























  Next we wanted to determine the rate at which the lipid conjugates modified the 
viruses since, to be of practical use, modification would need to take place more rapidly 
than the rate at which viruses spontaneously decay and lose their activity.  To determine 
if the lipid conjugates modify retrovirus particles on a time scale significantly shorter than 
the decay rate of the viruses, we incubated retrovirus stocks with DSPE-PEG-biotin (6 
µg/mL) at 4 °C for up to 5 hours, after which we flocculated and centrifuged the viruses 
to separate them from unincorporated lipid conjugates. The amount of virus and lipid 
conjugate in the pellet was then quantified by ELISA (Figure 2.4).  No significant 
differences (p > 0.05) in the amount of biotin that was incorporated into the virus 
particles were observed, even when the virus was incubated with the conjugate for only 
30 minutes.  These results indicate that the modification reaction occurs rapidly (i.e., in 
less than 30 minutes) and on a much shorter time scale than virus decay, which occurs 
with a half-life of about 7.5 hours at 37 °C and 14 days at 4 °C (27).   
Next, to determine if the lipid conjugates remain stably associated with the virus 
particles, we incubated retrovirus, which had been previously modified with DSPE-PEG-
biotin as described above, in TBS or in TBS and 10% fetal bovine serum (FBS) for 8 
hours at 4 °C or 37 °C.  We separated the retroviruses from unincorporated lipid 
conjugate by flocculation and centrifugation, and then quantified the amount of virus and 
lipid conjugate in the pellet by p30 and biotin ELISA.  We found that after 8 hours, 75 to 
90% of the lipid conjugates remained associated with the virus particles (Figure 2.5).  
The results suggest that more lipid conjugate disassociated from virus in the presence of 
serum (25%) than in its absence (10%), but the differences were not statistically 

















Figure 2.3 (A-D).  The DSPE-PEG-biotin lipid conjugate co-localizes with lentiviruses.  
GFP-labeled lentivirus (100 µL) (1x106 cfu/mL) was incubated (2 h at 4 °C) with DSPE-
PEG(2000)-biotin (2 µM) in TBS (modified) or with TBS only as a control (unmodified).  
Next, the samples were flocculated with Polybrene (320 µg/mL) for 30 min at 37 °C, 
pelleted by centrifugation (10,000 × g, 30 min) to separate the virus particles from 
excess unbound DSPE-PEG-biotin, and 10 µL of this sample was incubated (5 min at 37 
°C) with 10 µL solution of 5 µg/mL rhodamine-streptavidin in TBS.  After incubation, 10 
µL of the sample was visualized by epifluorescence microscopy (60 x).  Arrow 1 shows 
that, in samples of unmodified virus, (a) GFP fluorescence does not colocalize with (b) 
rhodamine fluorescence.  Arrow 2 shows that, in samples of viruses modified with lipid 
conjugate, (c) GFP fluorescence colocalizes with (d) rhodamine fluorescence.  The scale 































Figure 2.3 (E)  Modified virus particles co-localize with streptavidin.  The total number of 
particles (open bars) and the number of particles that colocalized with rhodamine-
streptavidin (closed bars) were counted in the modified and unmodified virus samples.  
Ten random fields of view were observed.  Statistically significant differences (p < 0.05) 
from the total number of virus particles counted are denoted with an asterisk.  Each point 






























































Figure 2.4  Lipid conjugates rapidly associate with retroviruses.  Retrovirus stock (100 
µL) was brought to 6 µg/mL of DSPE-PEG-biotin and incubated at 4 °C for 0.5, 1, 2, 5 
hours.  Next, to separate the virus particles from excess unbound DSPE-PEG-biotin, the 
samples were flocculated with Polybrene (320 µg/mL) for 30 min at 37 °C, pelleted by 
centrifugation (10,000 × g, 30 min), and resuspended in TBS (100 µL).  The amount of 
p30 (•) and biotin (ο) in the resuspended pellets were quantified by ELISA.  No statistical 
differences were observed in the amount of biotin at different time points (p < 0.05).  
Each point shows the mean and standard deviation of at least three replicate 














































































































Figure 2.5  Lipid conjugates stably associate with retroviruses.  Retrovirus stock (100 
µL) was brought to 6 µg/mL of DSPE-PEG-biotin, incubated for 2 h at 4 °C, flocculated 
with Polybrene (320 µg/mL) for 30 min at 37 °C, pelleted by centrifugation (10,000 × g, 
30 min), resuspended in 100 µL of TBS (TBS) or TBS with 10% fetal bovine serum 
(FBS), and incubated for 8 hours at 37 °C or 4 °C.   To separate the retroviruses from 
excess unbound DSPE-PEG-biotin, the samples were flocculated with Polybrene (320 
µg/mL) for 30 min at 37 °C, pelleted by centrifugation (10,000 × g, 30 min), and 
resuspended to their original volume in TBS.  Biotin in the virus samples before 
incubation (Control; open bar) and in the virus samples that were incubated for 8 hours 
at 37 °C (closed bars) and at 4 °C (stippled bars) were quantified by ELISA.  Statistically 
significant differences (p < 0.05) from the Control were denoted with an asterisk.  Each 







To determine if the modification of the viruses changed their binding properties, 
we incubated (30 min, 25 °C) modified retroviruses, or unmodified retroviruses as a 
control, in streptavidin-coated plates (70 µL/well), washed the plates three times (200 
µL/well) to remove unbound or loosely bound virus, and then quantified the amount of 
bound virus by ELISA (Figure 2.6).   The wells that had been incubated with modified 
virus contained 3-fold more virus than the wells that had been incubated with unmodified 
virus, which indicates that modification of the retroviruses with the biotinylated lipid 
conjugates increased their ability to bind streptavidin.  Finally, to determine if lipid-
modification altered the infectivity of the viruses, we measured the titer of modified and 
unmodified lacZ amphotropic retrovirus.  Interestingly, titers of the modified viruses were 
more than two fold higher (5.6 ± 0.4 x 106) than the unmodified viruses (2.5 ± 0.1 x 106) 
(p < 0.05).  To summarize the above results, we have found that the DSPE-PEG-biotin 
conjugates rapidly and stably modified the retrovirus particles, do not reduce their ability 
to infect cells, and increased by more than three-fold the number of viruses that bound to 



























Figure 2.6 Retroviruses modified with the DSPE-PEG-biotin lipid conjugate bind to 
strepavidin-coated plates.  Overnight centrifuged (4 °C at 6000 × g) virus stock was 
concentrated 10-fold in TBS and incubated (2 h at 4 °C) with DSPE-PEG-biotin (6 
µg/mL) in TBS (VL+PB), or, as a control, with TBS only (V+PB).  Next, the virus was 
flocculated with Polybrene (320 µg/mL), pelleted by centrifugation (10,000 × g, 30 min), 
resuspended to its original volume (100 µL) in 1 M NaCl, added to a well of a 
streptavidin coated plate, and centrifuged (3000 x g) for 30 min at room temperature.   
Wash buffer (3 times, 200 µL) was used to remove unbound virus, after which bound 
virus was resuspended with lysis buffer (100 µL), incubated for 30 min, and quantified by 
p30 ELISA.  We also incubated unmodified virus, in the absence of any Polybrene (V), 
with streptavidin coated plates as a negative control.  The amount of p30 that bound to 
the wells, as a fraction of the total amount that was added to the wells, is shown.  
Statistically significant differences (p < 0.05) from unmodified virus (V) are denoted with 






























































Lipids and lipid conjugates have been previously used to label viruses or to 
create virus-like particles, but this is the first study, to our knowledge, to use lipid 
conjugates to modify the binding properties of retroviruses.  Hoekstra et al. used 
octadecyl-rhodamine B, an amphiphilic fluorescent lipid dye, to label the lipid bilayers of 
influenza and Sendai virus particles (20).  The dye spontaneously incorporated into the 
lipid bilayer of the viruses in just one hour at room temperature, and incorporation of the 
dye did not adversely affect the ability of the viruses to fuse with target cells (3, 20, 46).  
The work by Hoekstra et al showed that it is possible to insert lipids into the viral 
membrane without affecting their function.  Lipid conjugates have also been used to 
confer new functions to lipid bilayers derived from viruses.  For example, Mastrobattista 
et al. generated virus-like particles by using detergent to solubilize the lipid bilayers of 
intact influenza viruses, which were then incubated with PEGylated lipid conjugates (30).  
The lipid conjugates were coupled to anti-epithelial glycoprotein-2 antibodies, which 
enabled the virus-like particles to efficiently bind to ovarian carcinoma cells (30, 46).   
The experiments of Mastrobattista et al showed that lipid conjugates can be used to alter 
the binding properties of virus-like particles, but the method used is not suitable for 
retroviruses since detergent solubilization would inactivate them.  In this study, we 
showed that lipid conjugates can be used to modify the binding properties of retrovirus 
particles without adversely affecting their ability to infect cells. 
The model lipid conjugate we used consisted of three components: a lipid anchor 
(DSPE), a flexible linker (PEG), and a binding moiety (biotin).  In principle, it should be 
possible to fine tune the physico-chemical characteristics of each of these components 
to optimize the effect the conjugate has on retrovirus binding and infection.  The lipid 
anchor is expected to control the extent and stability with which the conjugates are 
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incorporated into the viruses, the flexible linker is likely to influence the extent to which 
the viruses bind to cells via non-specific interactions, and the binding moiety will dictate 
which receptor and cell types the viruses bind to.  For example, several previous studies 
with liposomes suggest that the stability of lipid conjugates in phospholipid bilayers 
depends to a large extent on the structure and length of their lipid anchor and the lipids 
that compose the bilayer into which they are being inserted (11, 21, 40).  Pownall et al. 
found that lipid conjugates constructed with short alkyl chains (C6 and C12), transfer 
quickly out of lipid membranes because of their higher solubility in water as compared to 
conjugates with long alkyl chains (i.e., C16) which have stronger lipid-lipid hydrophobic 
interactions (21, 36).  Schutz et al. found that DMPE (1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine), a lipid probe composed of long saturated lipid alkyl chains, 
preferentially partitioned into detergent resistant regions of cellular membranes, which 
are largely composed of saturated alkyl chains with structures similar to that of DMPE  
(21, 42).  This and other studies suggest that lipid conjugates incorporate most efficiently 
into target membranes composed of lipids with similar structures (25, 37, 42).  In 
addition, several investigators have found that lipid conjugates composed of long 
saturated double-chain anchors remain incorporated in cellular lipid membranes longer 
than their monounsaturated double chain counterparts (7, 21, 25, 42).   Based on these 
findings, we used DSPE for the lipid anchor of our lipid conjugates because it is long 
(C18), saturated, double chained, and contains alkyl groups that are similar in structure 
to phosphatidylethanolamine (PE), a lipid that is present in abundance in the lipid bilayer 
of retroviruses (6). 
It is also interesting to consider how the physical characteristics of the flexible 
linker will affect the function of the lipid conjugates.  The flexible linker, if appropriately 
designed, could be used to shield the virus particles from binding to non-targeted 
molecules or surfaces (5, 10, 19, 31).  For example, Croyle et al. covalently linked PEG 
chains to free lysine residues on the surfaces of VSV-G pseudotyped lentiviruses, which 
protected the viruses from being bound to and inactivated by antibodies and 
 50 
complement in human and mouse sera (10).  The extent to which PEG chains are able 
to shield surfaces is primarily controlled by their length and number density (34).  We 
estimate, based on our measurements of virus-associated biotin (see Figure 2b), and 
assuming that the number of particles in our virus stocks was about 100-fold higher than 
their infectious titers (1, 27), that our modified virus particles contained about 500 
biotinylated lipid conjugates, or less than 2 mol% PEGylated lipid (14, 22).  Previous 
work showed that PEG chains of similar molecular weight as ours, when present at 
similarly low concentrations, protrude only about 7 nm from the surface of the lipid 
bilayer to which they are anchored (50).  In contrast, retroviral envelope proteins extend 
about 10 nm from the virus surface, which may explain why the lipid conjugates used in 
our study did not reduce virus titers (16).  In the future, it will be interesting to examine 
how changes in the length and density of the PEG chains affect virus binding and 
transduction, and to optimize the design of the lipid conjugates so that they are able to 
reduce the extent to which retroviruses bind to non-targeted cell types while still retaining 
their ability to efficiently bind to and transduce cells that express the targeted receptor.   
In conclusion, we have developed a novel method for modifying the surfaces of 
retrovirus particles with lipid conjugates.  The lipid conjugate used in this study, DSPE-
PEG-biotin, was composed of three distinct elements, each of which can be modified as 
needed to achieve the desired effect on retrovirus binding and infection.  We envision 
that lipid conjugates, similar to those used in this study, may prove useful for protecting 
viral vectors from complement inactivation, or for targeting them to specific cell types, or 
for improving their performance in vaccination protocols, such as by targeting them to 
specific types of immune system cells, or by using the lipid conjugates as adjuvants to 
alter the immunogenicity of the virus particles.   
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 The lipids of enveloped viruses play an important role in virus morphogenesis 
and infectivity.  These lipids are derived from host cell membranes during virus budding, 
which has been shown to occur in regions of the host cell that are enriched in cholesterol 
and sphingomyelin.  Sphingolipids have been implicated in a variety of pathogens to 
help facilitate the process by which viruses enter cells.  In this study, we used the fungal 
endotoxin myriocin (ISP-1) to inhibit de novo sphingolipid synthesis in virus producer 
cells.  We examined the effect on the lipid composition of virus producing cells and the 
virus particles produced from them.   Our results suggest that treating virus producer 
cells with ISP-1 can significantly alter the lipid composition of the viruses that they 
produce, and that these particles exhibit reduced infectivity in a cell-type dependant 
manner.  We investigated different steps involved in the virus infection pathway and 
found that virus particles produced from ISP-1 treated cells are less fusogenic as 
compared to viruses produced from untreated cells.  The implications of these results to 
improve gene therapy vectors and anti-retroviral therapies are discussed.   
 
 3.2 Introduction 
 Enveloped retrovirus vectors are one of the most commonly used viral vectors in 
clinical human gene therapy protocols (Wiley 2008).  Generally, the nucleic acid and 
protein content of amphotropic murine leukemia virus (A-MLV) are manipulated to 
enhance and control gene transfer (Wiley 2008).   The lipid composition of the viral 
vector is almost never altered in these protocols, mainly because the role of lipids in 
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virus fusion and infection, and the means to manipulate lipid composition, are less well 
established.     
 Retroviral entry into host cells is mediated by specific interactions between the 
virus envelope proteins and their cognate cellular receptors (1, 3).  Specifically, A-MLV 
surface glycoprotein gp70 initiates infection by binding to Pit2, which is a sodium-
dependant phosphate transporter that resides on the cell surface (8, 18).  This 
interaction triggers irreversible conformational changes in the envelope protein which 
allow the outer leaflets of the virus and cell lipid bilayers to mix and fuse in a process 
called hemifusion (1, 23).  Subsequently, the inner lipid bilayer leaflets complete the 
fusion process by inducing the formation of a pore, which allows the delivery of the virus 
capsid into the cytoplasm of the host cell (2, 23).   Although the impact of altering the 
composition of the virus lipid bilayer is unclear, there is increasing evidence that the lipid 
composition of virus particles plays a key role in virus function and may potentially be an 
important means to control gene transfer.   
Accumulating evidence suggests that lipids within the viral membrane are not 
incorporated randomly, and are heavily enriched in cholesterol and sphingomyelin (SM), 
possibly because retroviruses bud from specialized sites within the plasma membrane, 
called lipid rafts (15).  Previous studies have shown that cholesterol is important in 
retroviral membrane integrity and function.  Treatment of retroviruses with beta-
cyclodextrin, a cyclic oligosaccharide that sequesters cholesterol, changed the 
morphology of the viruses and reduced their infectivity (4).   Furthermore, several recent 
studies have demonstrated that depletion of lipids from target cells inhibits virus fusion 
and infection (4, 6, 16).  In addition, Hug et al found that blocking the sphingolipid (SL) 
biosynthesis in cells reduced their susceptibility to retrovirus infection, which suggests 
that the sphingolipids of retroviruses play a critical role in virus fusion (6).   Altogether, 
virus infection requires the interaction between viral envelope proteins and receptors on 
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the target cell.  This interaction has been extensively studied, yet the role that specific 
lipids play in virus fusion remains poorly understood.  We wondered if retroviruses 
require that their lipid bilayers contain specific types or amounts of lipids in order for 
fusion to occur efficiently.     
 Myriocin (ISP-1) is a potent inhibitor of serine palmitoyltransferase (SPT), an 
enzyme that is involved in the first step of the biosynthesis pathway of sphingolipid (17, 
22).  Myriocin has previously been shown to block HIV infection and replication in T-cell 
leukemia CEM cell line (17).  In this study, we determine the effect of blocking de novo 
sphingolipid biosynthesis on virus function by treating stably transfected virus producer 
cells with myriocin.   We investigated the mechanism and extent to which altering the 
lipid composition of retroviruses affects transduction.   
 
3.3 Material and Methods 
 Chemicals and Antibodies.  Myriocin was obtained from Biomol (Philadelphia, 
PA). Gluteraldehyde, and 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide 
(Polybrene, PB) were from Sigma Chemical Co. (St. Louis, MO). Hydrogen peroxide 
30%, and polyoxyethylene 20-sorbitan monolaurate (Tween 20) were from Fisher 
Scientific (Fair Lawn, NJ). Centrifugation filters to concentrate and purify virus stock 
were obtained from Millipore Corporation (Billerica, MA).  Non-fat dry milk (blotting 
grade) was from Bio-Rad Laboratories (Hercules, CA). o-phenylenediamine 
dihydrochloride (OPD) was from Pierce (Rockford, IL). 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal) was from Denville Scientific, Inc. (Metuchen, NJ). Mouse anti-
p30 and mouse anti-gp70 antibodies were purified from the supernatant of the CRL-
1219 (ATCC, Rockville, MD) and the 83A25 [NL 37] hybridoma cell lines respectively, 
following standard procedures [NL 38]. The goat polyclonal anti-p30 antibody (78S221) 
and the goat polyclonal anti-gp70 (79S834) were from Quality Biotech (Camden, NJ). 
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The horseradish peroxidase conjugated rabbit anti-goat immunoglobulin G polyclonal 
antibody was from Zymed Laboratories (South San Francisco, CA).   
 Cell Culture.  NIH 3T3 mouse fibroblast were cultured in Dulbecco's modified 
Eagle's medium (DMEM; Hyclone Labs Inc., Logan, UT) with 10% bovine calf serum 
(Hyclone Labs Inc.), 100 U/mL of penicillin, and 100 µg/mL of streptomycin (Hyclone 
Labs Inc.) (DMEM/BCS).  HeLa cells (human cervical kidney, ATCC) and 293T/17 cells 
(human embryonic kidney epithelial) were cultured in Dulbecco’s modified Eagle’s 
medium (Hyclone Labs Inc., Logan, UT) with 10% fetal bovine serum (Hyclone Labs 
Inc.), 100 U/mL of penicillin and 100 µg/mL of streptomycin (DMEM/FBS).  TELCeB6-A 
(TE671 (human rhabdomyosarcoma) cells stably transfected to express lacZ, Mo-
MLVgagpol (13) and the amphotropic envelope glycoprotein (10)) were cultured in 
DMEM, 10% fetal bovine serum (Hyclone Labs, Inc.), 100 U/mL of penicillin, and 100 
mg/mL of streptomycin (DMEM/FBS). 
 Virus Production.  To generate retrovirus particles, TELCeB6-A cells were 
grown to confluence in T175 tissue culture flasks, and then incubated for 24 h with 20 
mL of DMEM/FBS. The virus-laden tissue culture medium was harvested, filter-sterilized 
(0.45 µm), then frozen (-80 °C) for later use.   
 Diluted Titer Assay.  Ten-fold serial dilutions of lacZ virus stock were made in 
DMEM/BCS for NIH 3T3 transduction or in DMEM/FBS for HeLa transduction and were 
supplemented with Polybrene (8 µg/mL). A 1-mL amount per well was used to transduce 
NIH 3T3 cells or HeLa cells that had been seeded (5 x 104 per well or 8 x 104 per well, 
respectively) the previous day in a 12-well plate. Two days after the start of the 
transduction, the cells were fixed and stained for β-galactosidase activity with X-Gal. 
Colonies of lacZ+ cells (typically in clusters of 2, 4, or 8 blue cells) were counted with the 
aid of a dissecting microscope. At appropriate dilutions of the virus stock, the clusters of 
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blue cells were sufficiently spread over the dish such that each cluster arose from a 
single transduction event.  
 Myriocin treatment.  For all experiments using myriocin, Telceb6-A cells were 
incubated with the indicated concentration of myriocin for 24 h at 37 ºC in DMEM/FBS or 
DMEM/BCS, depending on the cell type to be transduced.   
 Lipid analysis of virus particles and cells.   Stably transfected virus producing 
cells, Telceb6-2A, and their parent cell line, Te671 which does not produce viruses, were 
used for lipid analysis.  Cells were grown to confluence in T175 flasks in DMEM/FBS.   
Telceb6-2A cells were then either treated with 0 µM or 10 µM myriocin.   Te671 cells 
were not treated with myriocin.  For three days at every 24 hrs, cell supernatant was 
collected, filter sterilized (0.45 µm), then frozen (-80 °C).  Harvested media was replaced 
with media either containing 0 µM or 10 µM myriocin.  As a control for lipids present in 
conditioned culture medium from cells not producing virus particles, the supernatant of 
untreated Te671 cells was similarly harvested each day for 3 days.  On the third day 
after harvest, the cells were put on ice and washed twice with cold phosphate buffered 
saline (PBS).  The cells were then lifted from the flask using a cell scraper, resuspended 
in PBS, counted using trypan blue and aliquoted in 13 x 100mm screw-capped, 
borosilicate glass test tubes at 107 cells per tube.  The cells were then centrifuged at 800 
x g at 4 ºC and the pellet was stored at -20 °C.    
 The filtered supernatant samples were concentrated using centrifugation filters 
from Millipore Corporation (Billerica, MA).   A concentrated volume of 1.5 mL to 2 mL 
was obtained.  The total volume was brought to 7 mL in DMEM/FBS for each sample 
and applied on top of a 2 mL 20% sucrose solution.  The virus particles were then 
pelleted by centrifugation at 30,000 rpm in a Beckman SW41 rotor for 2 h at 4 ºC.  The 
supernatant was gently aspirated, the pellet was resuspended in 400 µL PBS and the 
protein content quantified using the Coomassie Plus-200 protein assay reagent.  The 
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samples were stored in 13 x 100mm screw-capped, borosilicate glass test tubes with 
teflon caps and used for sphingolipid analysis.   
 The sphingolipid analyses were conducted by liquid chromatography (LC) and 
electrospray tandem mass spectrometry using a PE Sciex API 3000 triple quadrupole 
mass spectrometer equipped with a turbo ion-spray source, as described previously (AM 
methods).  Internal standards for the mass spectrometric analyses were obtained from 
Avanti Polar Lipids (Alabaster, AL); these were C12-ceramide (N-dodecanoyl-
sphingosine, d18:1/12:0), C12-glucosylceramide, and C12-sphingomyelin.  Protocol 
adapted from Merrill et al. Methods.  36: 207-224 (2005).   
 Cells and virus samples in the borosilicate glass test tubes were mixed with 
0.5ml of methanol then 0.25ml of chloroform and the internal standards.  The internal 
standards were prepared as a working stock in methanol and chloroform (2:1 v/v) such 
that small volumes can be added to each test tube.  In general, the internal standard 
mixture is prepared to deliver 0.5 nmol of each of the following (per sample): ceramide 
(d18:1/12:0-Cer), sphingomyelin (d18:1/12:0-SM), glucosylceramide (d18:1/12:0-
GlcCer), and lactosylceramide (d18:1/12:0-LacCer) (note that all have a 12-carbon fatty 
acid side chain), and C17-sphingosine, C17-sphinganine, C17-sphingosine 1-phosphate, 
and C17-sphinganine 1-phosphate (the C17-chain length was not found in most 
samples, and was verified for each new type of sample that was analyzed). All of these 
are available from Avanti Polar Lipids (Alabaster, AL).   The test tubes were then 
sonicated until they appeared evenly dispersed, then incubated overnight at 48 °C in a 
heating block.  The samples were then cooled to room temperature, 75 µL 1M KOH in 
methanol was added, sonicated, and incubated for 2 h at 37 °C.   These steps remove 
most of the interfering glycerolipids, in particular phosphatidylcholines that can mask 
sphingomyelins in a simple mass spectroscopy scan.   
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 The samples were cooled to room temperature and half of the volume was 
transferred to a new test tube. This portion (named Extract A) was used for separation of 
the more polar sphingolipids by reverse-phase LC.  The solvent was removed from the 
samples using a Speed Vac-type concentrator (ThermoSavant), and re-dissolved in the 
reverse-phase LC solvent.  To the half of the extract that remained in the original test 
tube, 3 µL of glacial acetic acid was added to bring the pH near neutral, then 1 mL of 
chloroform and 2 mL of water was added, sample was vortexed, and centrifuged to 
separate the phases.  The upper layer was carefully removed using a Pasteur pipette 
(discard), leaving the interface (with water).  The solvent was then evaporated from the 
lower layer (named Extract B) using a Speed Vac-type concentrator (ThermoSavant), 
and re-dissolved in the normal-phase LC solvent.   
 Protein assay.  To quantify the amount of protein in purified virus stocks after 
filtration, concentration and sucrose-cushion ultracentrifugation, samples were analyzed 
with the Coomassie Plus-200 Protein Assay as per the manufacturer’s protocol.  Optical 
density was measured using an absorbance plate reader (Pierce, Rockford, IL) and 
bovine serum albumin was used to create standards.   
 Cell viability assay.  Ten microliters per well of MTT solution (100 mg of MTT in 
1 mL of PBS) were added per well to cells in a 96-well plate. The plate was incubated for 
4 hours at 37°C, then 150 µL of 10% sodium dodecylsulfate (SDS) was added per well 
and the plate incubated overnight at 37oC.  The optical density at 570 nm was measured 
using an absorbance plate reader and the non-specific background at 650nm 
subtracted. Values for replicate wells without cells were subtracted as background. 
Values for each point are the average of triplicate wells. 
 Envelope function assay. To determine whether the structure of virus envelope 
protein (gp70) had been altered, amphotropic retroviruses produced with or without the 
treatment of myriocin were mixed with various concentration of gp70-specific monoclonal 
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antibody (83A25), and used to transduce NIH 3T3 cells.  An ONPG assay was then 
conducted to quantify the inhibition of virus infection due to 83A25 binding to gp70, the 
virus envelope protein.   
 Virus stability.  To determine virus particle stability, retrovirus (100 µL) produced 
from myriocin treated or untreated cells were incubated at 37 °C for 0 hr to 24 hrs.  At 
indicated time points, a small aliquot was collected and stored (-80 °C) for later use.  
These aliquots were then later used to transduce NIH 3T3 to determine virus activity.   
 ELISA for p30 and gp70.  The concentration of virus capsid protein and 
envelope protein, p30 and gp70 respectively, were quantified using a previously 
described enzyme-linked immunosorbent assay (ELISA) (10). Briefly, ELISA plates 
(Nunc immuno Maxisorp 96-well plates, Nalgen Nunc International, Rochester, NY) were 
coated overnight at 4 °C with 10 µg/mL of mouse anti-p30 antibody or mouse anti-gp70 
antibody (100 µL/well) in PBS. The next day, the antibody solution was removed and 
blocking buffer (PBS, 0.05% Tween-20, 5% non-fat milk) was added (200 µL/well) for 2 h 
at 37°C to block non-specific binding sites. Virus particles were lysed using 0.5% Triton-
X to expose the p30 antigen, then added to the ELISA plate (100 µL/well) and incubated 
for 1 h at 37 °C. Bound p30 and gp70 were sandwiched by either the addition of the goat 
polyclonal anti-p30 antibody diluted 1:1000 or goat polyclonal anti-gp70 antibody diluted 
1:300 in blocking buffer for 1 h at 37 °C (10), respectively. The horseradish peroxidase 
conjugated polyclonal rabbit anti-goat immunoglobulin G was diluted 1:5000 in blocking 
buffer and added to the ELISA plate (100 µL/well) for 1 h at 37 °C to enable detection 
and quantitation of the p30 or gp70 antigen. The plates were developed for 5 min using 
hydrogen peroxide (H2O2) and OPD (100 µg/well) from a solution of 3 mg of OPD and 3 
µl H2O2 in 7.5 mL of substrate buffer (24 mM citric acid-monohydrate, 51 mM Na2HPO4-
7H20, pH 5.0).  Sulfuric acid (8 N, 50 µL/well) was used to stop the reaction, the optical 
density at 490 nm was measured using an absorbance plate reader, and the non-
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specific background at 650 nm was subtracted. Values for replicate wells without virus 
were subtracted as background. 
 Beta-galactosidase (β-gal) transduction assay. Five thousand NIH 3T3 murine 
fibroblasts or eight thousand HeLa cells suspended in 100 µL of medium were plated in 
each well of a 96-well flat-bottomed tissue culture dish with a low-evaporation lid (Costar 
Corp., Cambridge, MA) (20). The next day, the medium was removed and 100 µL of the 
virus-containing solution was added to each well. Two days after transduction, the 
medium was removed and the cells washed once with 100 µL of PBS containing 1mM 
MgCl2. After removal of the wash solution, 50 µL of lysis buffer (PBS with 1mM MgCl2 
and 0.5% Igepal) were added to each well, and the plate incubated at 37 °C. After 30 
min, 50 µL of lysis buffer with 6 mM ONPG was warmed to 37 °C, added to each well, 
and the plate incubated at 37°C for 5 to 60 min until a visible yellow color was obtained. 
The reactions were halted by the addition of 20 µL per well of stop buffer (1M Na2CO3). 
The optical density at 420 nm (OD420) was measured using an absorbance plate reader 
(Molecular Devices, Menlo Park, CA) and the non-specific background at 650 nm 
subtracted. Values for replicate wells without virus were subtracted as background. 
Values for each point are the averages of at least triplicate wells. 
 Virus binding assay.  To determine if myriocin treatment altered virus binding, 
we incubated virus produced from varying doses of myriocin with NIH 3T3 cells and 
HeLa cells.  NIH 3T3 or HeLa cells were plated to confluence in 6 well plates.  The next 
day virus supernatant was applied to cells and incubated at 4 °C for 2 hrs.  The cells 
were washed twice with cold PBS, lifted from the wells using a cell scraper, centrifuged 
(800 x g for 5 min) and the pellet resuspended in lysis buffer.  Cell lysis samples were 
then used to quantify virus protein using the p30 ELISA.   
 Production of nef-luc laz retrovirus.  Telceb6-A cells were plated at 
approximately 80% confluency in 10-cm tissue culture dishes.  The cells were 
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transfected with 8 µg of pcDNA3-Nef-luc (kind gift of Robert Davey), diluted in 1.5 mL of 
DMEM, mixed with a solution of 1.5 mL of DMEM and 40 µL of Lipofectamine 2000 
reagent (Invitrogen Life Technologies, Carlsbad, CA) and then added to the cells. The 
medium was replaced 6 hours later and 18 hours later with 10 mL of DMEM/FBS. 
Twenty four hours later the supernatant was removed from the cells and replaced with 
media containing varying concentrations of myriocin.  After 24 hrs of treatment, the virus-
laden cell culture supernatant was harvested, filter sterilized (0.45-µm) and frozen (-
80°C) for later use.  Virus capsid protein was quantified using p30 ELISA.      
 Virus Fusion assay.  NIH 3T3 and HeLa cells were trypsinzed, counted and 
pelleted in 1.5 mL tubes such that each pellet contained 1 x 105 cells.  This protocol is 
adapted from Saeed et al (19).   The cells were resuspended in 100 µL containing equal 
amount of virus protein (p30).  Virus and cells were incubated at 37 °C for 2 hrs on a 
rotating platform.  To remove virus particles that had not fused with the cell membrane, 
the cells were pelleted by centrifugation at 800 x g for 5 min, supernatant discarded, and 
the cell pellet washed twice in DMEM.  The final cell pellet was resuspended in 0.1 mL of 
Luciferase Assay Buffer (Promega) and the luciferase activity was measured using a 
Turner Biosystems Modulus Microplate reader and expressed as relative luciferase 
units.   
 Statistical Analysis.  Data are summarized as the mean ± one standard 
deviation for triplicate samples.  Statistical analysis was performed using one-way 
analysis of variance for repeated measurements of the same variable.  The Tukey 
multiple comparison test was used to conduct pairwise comparisons between means.  






 During virus budding, viruses acquire a lipid bilayer composed of signaling 
proteins and host lipids, both of which play a significant role in virus attachment, fusion 
and entry (14, 23).   Although envelope proteins have been extensively studied and 
manipulated, little is known about the role lipids play in mediating virus binding and 
infection.  Here we studied the effect of blocking de novo sphingolipid biosynthesis on 
virus function by treating virus producing cells with myriocin (ISP-1), a potent inhibitor of 
serine palmitoyl-CoA transferase (SPT), which is a rate limiting enzyme in the 
biosynthesis of sphingolipids (Figure 3.1) (Hojjati et al 2005).   
 As a first step toward investigating the effects of altering sphingolipid synthesis 
we wanted to determine the effect of treating the virus producer cells with ISP-1 on the 
lipid composition of the viruses that they produce, and on the composition of the cellular 
membrane. We treated TelCeB6 cells with 10 µM ISP-1 for 24 hours, or left them 
untreated, harvested the virus supernatant and analyzed the lipid composition of the 
cells and virus particles using mass spectrometry (Figure 3.2 A-F).  After virus producer 
cells were treated with ISP-1, they were washed with cold PBS three times, counted, 
pelleted and stored at – 20oC.  We also analyzed the lipid content of Te671 cells, the 
parent cell line of TelCeB6 cells, as a control to quantify the amount and type of lipids 
that are not virus-associated that are present in the conditioned medium.  Conditioned 
medium, which was collected from cultures of Te671, TelCeB6, and TelCeB6 cells that 
had been treated with 10 µM ISP-1, was thawed, concentrated, pelleted and purified two 
times with a 20 % sucrose cushion.   Equal amount of virus protein was then used for 
lipid analysis using mass spectroscopy.  Lipids were extracted from pellets of cells and 
supernatant and analyzed for three downstream products in the lipid synthesis pathway 
affected by ISP-1: ceramide, glycosylceramide and sphingomyelin.  Cells treated with 




















Figure 3.1: The pathway of de novo sphingolipid biosynthesis and sites of action of 












































Figure 3.2 (A) Mass spectrometry analysis of ceramide present in virus producer 
cells.  Stably transfected virus producing cells, Telceb6-2A, and their parent cell line, 
Te671 which does not produce viruses, were used for lipid analysis.  Cells were grown 
to confluence in T175 flasks in DMEM/FBS.   Telceb6-2A cells were then either treated 
with 0 µM or 10 µM myriocin.   Te671 cells were not treated with myriocin.  Every 24 hrs, 
for 72 hours, cell supernatant was collected, filter sterilized (0.45 µm), then frozen (-80 
°C).  Harvested media was replaced with media either containing 0 µM or 10 µM 
myriocin.  As a control for lipids present in conditioned culture medium from cells not 
producing virus particles, the supernatant of untreated Te671 cells was similarly 
harvested each day for 3 days.  On the third day after harvest, the cells were put on ice 
and washed twice with cold phosphate buffered saline (PBS).  Cells were then lifted from 
the flask using a cell scraper, resuspended in PBS, counted and aliquoted in borosilicate 
glass test tubes at 107 cells per tube and pelleted centrifuged at 800 x g at 4 ºC.     (*) 












































Figure 3.2 (B) Mass spectrometry analysis of glucosylceramides present in virus 
producer cells.  Stably transfected virus producing cells, Telceb6-2A, and their parent 
cell line, Te671 which does not produce viruses, were used for lipid analysis.  Cells were 
grown to confluence in T175 flasks in DMEM/FBS.   Telceb6-2A cells were then either 
treated with 0 µM or 10 µM myriocin.   Te671 cells were not treated with myriocin.  Every 
24 hrs, for 72 hours, cell supernatant was collected, filter sterilized (0.45 µm), then 
frozen (-80 °C).  Harvested media was replaced with media either containing 0 µM or 10 
µM myriocin.  As a control for lipids present in conditioned culture medium from cells not 
producing virus particles, the supernatant of untreated Te671 cells was similarly 
harvested each day for 3 days.  On the third day after harvest, the cells were put on ice 
and washed twice with cold phosphate buffered saline (PBS).  Cells were then lifted from 
the flask using a cell scraper, resuspended in PBS, counted and aliquoted in borosilicate 
glass test tubes at 107 cells per tube and pelleted centrifuged at 800 x g at 4 ºC.   (*) 










































Figure 3.2 (C) Mass spectrometry analysis of sphingomyelin present in virus 
producer cells.  Stably transfected virus producing cells, Telceb6-2A, and their parent 
cell line, Te671 which does not produce viruses, were used for lipid analysis.  Cells were 
grown to confluence in T175 flasks in DMEM/FBS.   Telceb6-2A cells were then either 
treated with 0 µM or 10 µM myriocin.   Te671 cells were not treated with myriocin.  Every 
24 hrs, for 72 hours, cell supernatant was collected, filter sterilized (0.45 µm), then 
frozen (-80 °C).  Harvested media was replaced with media either containing 0 µM or 10 
µM myriocin.  As a control for lipids present in conditioned culture medium from cells not 
producing virus particles, the supernatant of untreated Te671 cells was similarly 
harvested each day for 3 days.  On the third day after harvest, the cells were put on ice 
and washed twice with cold phosphate buffered saline (PBS).  Cells were then lifted from 
the flask using a cell scraper, resuspended in PBS, counted and aliquoted in borosilicate 
glass test tubes at 107 cells per tube and pelleted centrifuged at 800 x g at 4 ºC.     (*) 






















































Figure 3.2 (D) Mass spectrometry analysis of ceramide in virus particles. Virus 
producer cells were treated as indicated in Figure 4.2 (A-C).  The filtered supernatant 
samples were concentrated using centrifugation filters from Millipore Corporation 
(Billerica, MA).   A concentrated volume of 1.5 mL to 2 mL was obtained.  The total 
volume was brought to 7 mL in DMEM/FBS for each sample and applied on top of a 2 
mL 20% sucrose solution.  The virus particles were then pelleted by centrifugation at 
30,000 rpm in a Beckman SW41 rotor for 2 h at 4 ºC.  The supernatant was gently 
aspirated, the pellet was resuspended in 400 µL PBS and the protein content quantified 
using the Coomassie Plus-200 protein assay reagent.  The samples were stored in 13 x 
100mm screw-capped, borosilicate glass test tubes with teflon caps and used for 
sphingolipid analysis.  (*) denotes statistically significant differences between treated 


















































Figure 3.2 (E) Mass spectrometry analysis glucosylceramides in virus particles. 
Virus producer cells were treated as indicated in Figure 4.2 (A-C).  The filtered 
supernatant samples were concentrated using centrifugation filters from Millipore 
Corporation (Billerica, MA).   A concentrated volume of 1.5 mL to 2 mL was obtained.  
The total volume was brought to 7 mL in DMEM/FBS for each sample and applied on top 
of a 2 mL 20% sucrose solution.  The virus particles were then pelleted by centrifugation 
at 30,000 rpm in a Beckman SW41 rotor for 2 h at 4 ºC.  The supernatant was gently 
aspirated, the pellet was resuspended in 400 µL PBS and the protein content quantified 
using the Coomassie Plus-200 protein assay reagent.  The samples were stored in 13 x 
100mm screw-capped, borosilicate glass test tubes with teflon caps and used for 
sphingolipid analysis.  (*) denotes statistically significant differences between treated 















































Figure 3.2 (F) Mass spectrometry analysis of sphingomyelin in virus particles.  
Virus producer cells were treated as indicated in Figure 3.2 (A-C).  The filtered 
supernatant samples were concentrated using centrifugation filters from Millipore 
Corporation (Billerica, MA).   A concentrated volume of 1.5 mL to 2 mL was obtained.  
The total volume was brought to 7 mL in DMEM/FBS for each sample and applied on top 
of a 2 mL 20% sucrose solution.  The virus particles were then pelleted by centrifugation 
at 30,000 rpm in a Beckman SW41 rotor for 2 h at 4 ºC.  The supernatant was gently 
aspirated, the pellet was resuspended in 400 µL PBS and the protein content quantified 
using the Coomassie Plus-200 protein assay reagent.  The samples were stored in 13 x 
100mm screw-capped, borosilicate glass test tubes with teflon caps and used for 
sphingolipid analysis.  (*) denotes statistically significant differences between treated 






















sphingolipids as compared to untreated TelCeB6 cells.  Since Te671 cells do no 
produce virus particles, the concentration of sphingolipids in Te671 supernatant was 
much lower than untreated TelCeB6 cells, as expected.    
 To determine the effect of ISP-1 treatment on virus production and infection, we 
treated a virus producing cell line (TelCeB6) with ISP-1 (0 to 30 µM) and harvested the 
virus supernatant after 24 hours.  We quantified the amount of virus produced by the 
treated cells using an ELISA for the viral capsid protein, p30 (Figure 3.3 A).  
Furthermore, the virus infectivity was measured by incubating particles with NIH 3T3 
cells and HeLa cells for 48 hours and conducting an ONPG assay (Figure 3.3 B).  Our 
data shows treating virus producer cells with 30 µM ISP-1 did not affect virus production 
but it reduced the ability of the resulting virus particles to infect NIH 3T3 cells to 70%, 
and the infectivity to HeLa cells was reduced to 15%.   To determine whether the 
decrease in infectivity was due to cell death after ISP-1 treatment, we measured the 
viability of the virus producing cells and the cells that were being transduced (Figure 
3.4).  Our results show that ISP-1 did not alter the viability of the cells, which indicates 
that the decreases in virus titer that were observed were not due to cytotoxic effects of 
the drug.   
 In order to determine the mechanism by which changes in the lipid content lead 
to changes in retrovirus transduction, we investigated different factors that may affect the 
fusion pathway.  First, we determined whether changing the lipid content of virus 
producer cells had altered the number of envelope proteins incorporated into virus 
particles.  We measured the extent of fusion protein (gp70) incorporation into virus 
particles produced from ISP-1 treated cells by ELISA (Figure 3.5 A).  Furthermore, we 
hypothesized that changing the lipid environment in the virus bilayer may also affect the 





























Figure 3.3 (A) Myriocin treatment does not affect virus production.   Virus producer 
cells, TelCeB6, were plated at 240, 000 cells per well of a 6-well plate and grown to 
confluency.  The next day, cell culture media was removed and replaced with media 
containing varying doses of ISP-1 as indicated.  After 24 hours, the conditioned cell 
media was collected and filter sterilized (0.45 µm).   The concentration of virus in the 
supernatant after treating virus producing cells with different doses of ISP-1 was 
determined using the p30 ELISA.  Each point shows the mean ± standard deviation of 















































Figure 3.3 (B) Treatment of virus producer cells with ISP-1 decreases the titer of 
the virus produced from those cells.  Virus stock was produced after various doses of 
ISP-1 treatment of TeLceB6 cells.  NIH 3T3 cells were plated at 60 000 cells per well 
and HeLa cells were plated at 80 000 cells per well of 96 well plates.  The next day, the 
ten-fold serial dilutions of virus stock were made in DMEM/BCS for NIH 3T3 transduction 
or in DMEM/FBS for HeLa transduction, supplemented with Polybrene (8 µg/mL) and 
incubated with cells.  Two days after the start of the transduction, the cells were fixed 
and stained for β-galactosidase activity with X-Gal. Colonies were counted with the aid 
of a dissecting microscope. At appropriate dilutions of the virus stock, the clusters of 
blue cells were sufficiently spread over the dish such that each cluster arose from a 


































































Figure 3.4 Effect of ISP-1 treatment on cell viability.  Virus producer cell line 
(TelCeb6) and target cells (NIH 3T3 and HeLa cells) were plated at a density of 10,000 
cells per well and 5,000 cells per well in 96-well plates.  The next day, the cells were 
treated with varying doses of ISP-1 as indicated.  TelCeb6 were assayed for cell viability 
after 24 hours of ISP-1 treatment and NIH 3T3 and HeLa cells were assayed after 48 
hours of treatment.   After 24 or 48 hours, 10 µL per well of MTT solution (100 mg of 
MTT in 1 mL of PBS) were added per well to cells in a 96-well plate. The plate was 
incubated for 4 hours at 37°C, then 150 µL of 10% SDS were added per well and the 
plate incubated overnight. The optical density at 570 nm was measured using an 
absorbance plate reader and the non-specific background at 650nm subtracted. Values 
for replicate wells without cells were subtracted as background. Values for each point 


























 virus bilayer.  Therefore, to determine whether the structure and function of the 
envelope protein, gp70, was affected, we measured virus transduction in the presence of 
an envelope-specific monoclonal antibody, 83A25 (Figure 3.5 B).  This antibody detects 
a specific structural motif on the ectodomain of the gp70 protein, and hence, would not 
bind to the gp70 protein with the same affinity if the protein significantly changed in 
structure.  Therefore, we would observe a lower IC50 for virus particles produced from 
ISP-1 treated virus producer cells than untreated cells.  Our results show that there was 
no statistical difference between the IC50 of virus particles produced after ISP-1 
treatment as compared to untreated cells.  We obtained IC50 values of 4.5 µg/mL for 30 
µM and 4.7 µg/mL for control virus.  To further determine if altering the lipid composition 
of virus particles affected gp70-dependant fusion of virus particles, we mixed virus 
produced from cells treated with various concentration of ISP-1 concentrations in media 
containing free gp70 and incubated with 3T3 cells to measure the effect on transduction 
(Figure 3.6 A-B).  We found an approximately 50% reduction in infection occurred for all 
samples of virus when they were incubated in the presence of 25% (by volume) of free 
gp70.    In addition, we observed a decrease in infection with increasing amount of free 
gp70 and found that the inhibitory concentration of gp70 for all virus samples was 
similar.  These results indicate that ISP-1 treatment does not reduce envelope 
incorporation into virus particles.    Altogether, this data suggests that the structure of the 
envelope proteins is not significantly different in the control viruses as compared to 
viruses produced from the ISP-1 treatment.   
 Changing the lipid content of virus producing cells may also affect the stability of 
the virus that is produced from those cells, as has been shown to be the case with 
cholesterol depletion.  To determine the stability of ISP-1 treated virus particles, we 
incubated virus at 37oC for up to 24 hours, after which we used samples from different 




























Figure 3.5 (A) Myriocin treatment does not affect amount of gp70 incorporation 
into virus particles.   Virus producer cells, TelCeB6, were plated at 240, 000 cells per 
well of a 6-well plate and grown to confluency.  The next day, cell culture media was 
removed and replaced with media containing varying doses of ISP-1 as indicated.  After 
24 hours, the conditioned cell media was collected and filter sterilized (0.45 µm).   The 
concentration of virus in the supernatant after treating virus producer cells with different 
doses of ISP-1 was determined using the gp70 ELISA.  Each point shows the mean ± 


































































Figure 3.5 (B). Myriocin treatment of virus producer cells does not affect structure 
of the gp70 incorporated into the virus particles.  Virus stock was produced by 
treating virus producing cells with 0, 10 or 30 µM ISP-1.  Virus samples were mixed with 
various concentrations with gp70-specific monoclonal antibody (83A25) as indicated, 
and the mixture was used to transduce NIH 3T3 cells which has been plated at a 5 000 
cells per well of a 96 well one day earlier.    Two days later, the ONPG assay was 
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Figure 3.6(A). Treating virus producer cells with ISP-1 does not decrease the 
amount of gp70 incorporated into the virus particles.  Virus particles were produced 
from the treatment of Telceb6 cells with 0, 10 or 30 µM ISP-1.  Virus particles were 
diluted in various concentrations of free gp70 as indicated, and the mixture was to 
transduce NIH 3T3 cells which has been plated at a 5 000 cells per well of a 96 well one 
day earlier.    Two days later, the ONPG assay was conducted to quantify the virus 
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Figure 3.6(B). Treating virus producer cells with ISP-1 does not decrease the 
amount of gp70 incorporated into the virus particles.  Data from part (A) is was 
normalized to the level of infection obtained in the absence of gp70 (maximal infection).   
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Figure 3.7. Stability of virus particles is not affected by myriocin treatment.  
TelCeb6 cells were plated at 240 000 cells per well in 6-well plates.  The next day, the 
cell culture media was supplemented with 0, 10 or 30 µM ISP-1.  After 24 hours, the 
virus supernatant was harvested and filter sterilized.  Retrovirus (100 µL) produced from 
ISP-1 treated or untreated virus producing cells were incubated at 37 °C for 0 hr to 24 
hrs.  At indicated time points, a small aliquot was collected and stored (-80 °C) for later 
use.  These aliquots were then later used to transduce NIH 3T3 to determine virus 
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similar to untreated virus at all time points measured, indicating that altering lipid content 
in the virus lipid bilayer did not affect the stability of the virus particles.   To determine if 
ISP-1 treatment altered virus binding properties, we harvested virus from Telceb6 cells 
after ISP-1 treatment as before, mixed in a 100,000 3T3 cells or HeLa cells at 4 oC for 2 
hours, washed twice with cold PBS, lysed the cells and quantified p30, the virus capsid 
protein (Figure 3.8).  We found that untreated virus bound to both cell types to the same 
extent as ISP-1 treated virus, suggesting that ISP-1 does not adversely affect the virus 
binding the cell surface.   
 Next we tested the fusogenicity of ISP-1 treated virus particles by using the nef-
luciferase assay (9).  In this experiment, virus producer cells were plated to confluency, 
transfected with 8 µg of pcDNA3-Nef-luc using Lipofectamine.  This plasmid contained 
the nef gene tagged with a gene for luciferase, allowing for the measurement of 
luciferase activity after virus particles fused with the target membrane and released the 
substrate into the cytoplasm of the cells.   Interestingly, we found that levels of luciferase 
activity decreased by about 25% in NIH 3T3 at dose of 30 µM ISP-1 and a decrease of 
nearly 80% treated in HeLa cells at similar concentrations of ISP-1 (Figure 3.9).  Also, 
the extent of reduction in luciferase activity corresponded to the extent of reduction in 
virus infection after ISP-1 treatment.  Therefore, our data suggests that depleting lipids 
from virus particles reduces their infectivity by altering their ability to fuse with the target 
cell membrane.   
 The presence of specific lipids in the virus lipid bilayer has been shown to be 
important for successful virus infection to occur, however, it is also known that the lipids 
in the target cell plasma membrane also contribute to efficient virus infection.   
Therefore, we wanted to determine whether the difference in infection of ISP-1 treated 
virus in NIH 3T3 and HeLa cells (Figure 3.10) was due to the lipid composition of the 




























Figure 3.8 Binding of virus particles produced from myriocin treated virus 
producer cells is not adversely affected. NIH 3T3 or HeLa cells were plated to 
confluence in 6 well plates.  The next day virus produced after various concentrations of 
ISP-1 treatment of virus producing cells, was applied to cells and incubated at 4 °C for 2 
hrs.  The cells were washed twice with cold PBS, lifted from the wells using a cell 
scraper, centrifuged (800 x g for 5 min) and the pellet resuspended in lysis buffer.  Cell 







































































Figure 3.9 Virus particles produced by ISP-1 treated cells fuses less efficiently 
with target cells membrane.   Telceb6-A cells were plated at approximately 80% 
confluency in 10-cm tissue culture dishes.  The cells were transfected with 8 µg of 
pcDNA3-Nef-luc using Lipofectamine and added to the cells. The medium was replaced 
6 hours later and replaced with DMEM/FBS. After 24 hours the supernatant was 
removed from the cells and replaced with media containing varying concentrations of 
ISP-1.  After 24 hrs of treatment, the virus-laden cell culture supernatant was harvested, 
filter sterilized (0.45-µm) and used to infect NIH 3T3 and HeLa cells.  NIH 3T3 and HeLa 
cells were incubated with virus at 37 °C for 2 hrs on a rotating platform.  After this, the 
cells were pelleted by centrifugation at 800 x g for 5 min, supernatant discarded, and the 
cell pellet washed twice in DMEM.  The final cell pellet was resuspended in 0.1 mL of 
Luciferase Assay Buffer (Promega) and the luciferase activity was measured using a 
Turner Biosystems Modulus Microplate reader and expressed as relative luciferase 

























































































































Figure 3.10 (A). Mass spectrometry analysis of ceramide present in the target cell 
membranes before and after myriocin treatment.  Target cells, 3T3 cell and HeLa 
cells were grown to confluence in T175 flasks in DMEM/BCS and DMEM/FBS, 
respectively.   Cells were then either treated with 0 µM or 10 µM ISP-1 for 72 hours and 
every 24 hrs, cell supernatant was changed with fresh media.  After 3 days of ISP-1 
treatment, the cells were put on ice and washed twice with cold phosphate buffered 
saline (PBS).  Cells were then lifted from the flask using a cell scraper, resuspended in 
PBS, counted and aliquoted in borosilicate glass test tubes at 107 cells per tube and 
pelleted centrifuged at 800 x g at 4 ºC.     (*) denotes statistical significant differences 












































Figure 3.10 (B). Mass spectrometry analysis of glucosylceramide present in the 
target cell membranes before and after myriocin treatment.  Target cells, 3T3 cell 
and HeLa cells were grown to confluence in T175 flasks in DMEM/BCS and DMEM/FBS, 
respectively.    Cells were then either treated with 0 µM or 10 µM ISP-1 for 72 hours and 
every 24 hrs, cell supernatant was changed with fresh media.  After 3 days of ISP-1 
treatment, the cells were put on ice and washed twice with cold phosphate buffered 
saline (PBS).  Cells were then lifted from the flask using a cell scraper, resuspended in 
PBS, counted and aliquoted in borosilicate glass test tubes at 107 cells per tube and 
pelleted centrifuged at 800 x g at 4 ºC.     (*) denotes statistically significant differences 



















































Figure 3.10 (C). Mass spectrometry analysis of sphingomyelin present in the 
target cell membranes before and after myriocin treatment.  Target cells, 3T3 cell 
and HeLa cells were grown to confluence in T175 flasks in DMEM/BCS and DMEM/FBS, 
respectively.    Cells were then either treated with 0 µM or 10 µM ISP-1 for 72 hours and 
every 24 hrs, cell supernatant was changed with fresh media.  After 3 days of ISP-1 
treatment, the cells were put on ice and washed twice with cold phosphate buffered 
saline (PBS).  Cells were then lifted from the flask using a cell scraper, resuspended in 
PBS, counted and aliquoted in borosilicate glass test tubes at 107 cells per tube and 
pelleted centrifuged at 800 x g at 4 ºC.     (*) denotes statistically significant differences 




































 (Figure 3.10 A-C).  We measured the levels of sphingolipids (specifically ceramide, 
glucosylceramide and sphingomyelin) in the two target cell types before and after 10 µM 
ISP-1 treatment.  We found that HeLa cells contained slightly more ceramide and 
sphingomyelin as compared to NIH 3T3 cells. The levels of glucosylceramide were 
similar for both cell types.  As expected, after ISP-1 treatment the level of all three 
sphingolipids significantly decreased.   The level of decrease between the two cell types 
was similar for all sphingolipids.  Our results also suggest that the lipid composition of 
the two cell types is similar.   
 Lastly, since the virus lipid bilayer must work cooperatively with the cell 
membrane lipids for efficient fusion to occur, we measured the infectivity of ISP-1 treated 
or untreated virus particles on the two target cell types after the cells had been ISP-1 
treated (Figure 3.11 A-B).  The target cells were plated and the cell culture medium was 
supplemented with various concentrations of ISP-1.  After 12 hours of treatment, the 
cells were incubated with virus particles, either produced from untreated or ISP-1 treated 
virus producer cells.  Our data indicates that treating target cells with even low doses of 
ISP-1 causes a significant decrease in infection for all virus samples.  Furthermore, the 
extent to which infection was inhibited was higher for HeLa cells after ISP-1 treatment 
than for NIH 3T3 cells, indicating that sphingolipids in HeLa cell membranes is critical for 
virus fusion.  Therefore, the significant decrease in infection after ISP-1 treatment of 
target cells implies that the presence of sphingolipids is not only important in the virus 

































Figure 3.11. (A) Treatment of NIH 3T3 cells with ISP-1 decreases virus infection.  
Virus was produced from the treatment of Telceb6 cells with ISP-1 with concentrations of 
0 µM, 10 µM and 30µM.  After 24 hours the virus was harvested and diluted in a range of 
concentrations of ISP-1, as indicated, and this mixture was used to transduce NIH 3T3 
cells.  NIH 3T3 cells had been plated at 5 000 cells per well of a 96 well one day earlier.  




















































Figure 3.11 (B). Treatment of HeLa cells with ISP-1 decreases virus infection.  Virus 
was produced from the treatment of Telceb6 cells with ISP-1 with concentrations of 0 
µM, 10 µM and 30µM.  After 24 hours the virus was harvested and diluted in a range of 
concentrations of ISP-1, as indicated, and this mixture was used to transduce HeLa 
cells.  HeLa cells had been plated at 8 000 cells per well of a 96 well one day earlier.  
Two days later, the ONPG assay was conducted to quantify the virus infection.   
 
 





















































 3.5 Discussion 
 Fusion between the virus lipid bilayer and the host membrane is absolutely 
required for retrovirus infection to occur.  Once virus envelope proteins interact with their 
cognate cellular receptors, several envelope glycoproteins oligomerize and assemble 
into a viral fusion machine which facilitates the movement of the two membranes into 
close apposition to allow fusion events to occur (1, 3, 23).  Both viral and cellular lipids 
and proteins mediate the formation and expansion of the fusion pore (5, 21).  Retroviral 
lipid bilayers are enriched in cholesterol and sphingolipids, and many studies have found 
that changes in the concentration of these components in the virus membrane can 
modulate viral fusion and entry (6, 16, 17).   
 In recent years, several groups have investigated the contribution of the 
cholesterol and sphingolipids to retrovirus entry and fusion (17).   For example, Liao et al 
have shown that when cholesterol synthesis is inhibited in retrovirus producer cells or 
when cholesterol is extracted from target cells, virus production and infection is 
significantly reduced (11).  Similarly, sphingolipid synthesis has been blocked in target 
cells to study the effects of complex sphingolipids (glycosphingolipids) in virus fusion and 
infection.  The inhibition of human immunodeficiency virus (HIV-1) fusion in CD-positive 
cell lines has been shown to occur after glycosphingolipids depletion.   
To test whether altering the levels of sphingolipids is important for MLV 
production and infection, we treated virus producer cells with myriocin (ISP-1).  ISP-1 
blocks the first step of the sphingolipid biosynthesis pathway, which causes significant 
changes in the cellular concentrations of many downstream bioactive intermediates, 
including ceramides, sphingomyelin and glucosylceramide.   We analyzed the effect of 
myriocin treatment on the lipid composition of the cells and found that there was 
significant reduction in the amount of sphingolipids in the myriocin treated cells as 
compared to untreated cells.  Specifically, ceramide levels were reduced by 94% 
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ceramide, glucosylceramide levels were reduced by 80%, and sphingomyelin were 
reduced by 70%.  Furthermore, we purified and analyzed the virus particles that were 
produced by cells that had been treated with ISP-1.  The virus particles contained 
significantly lower concentrations of sphingolipids as compared to virus particles that 
were produced from untreated cells.  Reductions of approximately 90% in ceramides, 
60% glucosylceramides, and 60% sphingomyelin were observed for the different species 
of sphingolipids.     
 Next we analyzed the effect of virus production and infection after ISP-1 
treatment.  Results from measuring virus capsid protein in stocks 24 hrs after ISP-1 
treatment indicate that the treatment had no significant effect on virus production or 
release.  Interestingly, we observed a reproducible decrease in virus infectivity.  Virus 
particles released from ISP-1 treated cells (30 µM) were 10-fold less infectious to HeLa 
cells than virus produced from untreated cells.  Our results suggest that the changes in 
virus infectivity after ISP-1 treatment were cell-type dependant.  When ISP-1 treated 
virus were incubated with NIH 3T3, the virus particles retained 70% of their infectivity 
versus an almost 10% infectivity in HeLa cells. These results suggest that the 
concentration of sphingolipids in the lipid bilayers of retroviruses appears to be important 
for maintaining virus infectivity but are not required for virus budding.   Since ISP-1 can 
have cytotoxic effects, we wondered if the decrease in virus infectivity was due a 
decrease in cell number after ISP-1 treatment.  Our cell viability assays indicate that 
there was no significance difference in viability of the target cells or virus producing cells 
after ISP-1 treatment.     
 Changing the lipid content of virus producing cells has been shown to cause 
severe changes in virus stability (6, 11).  For instance, depletion of cholesterol from virus 
particles or virus producing cells has been shown to inactivate virus particles (11).  Our 
results indicate that the stability of virus particles produced from ISP-1 treated cells was 
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similar to that of virus particles produced from untreated cells.   Lastly, we investigated 
the ability of the virus particles to fuse with the target cell membrane.  Interestingly, we 
observed similar trends in fusiogenicity of the virus particles as we had with virus 
infection.  Depleting lipids from virus particles reduced their infectivity by altering their 
ability to fuse with the target cell membrane.   
The presence of specific lipids in the virus lipid bilayer have been shown to be 
important for successful virus infection to occur, however, it is also known that the lipids 
in the target cell plasma membrane also contribute to efficient virus infection.   
Treatment of target cells with 10 µM ISP-1 resulted in significant decreases in the cell 
membrane.  We observed 6 to10 fold decreases in sphingolipids in both cell types for all 
three species of sphingolipids.  Furthermore, since the virus lipid bilayer must work 
cooperatively with the cell membrane lipids for efficient fusion to occur, we measured the 
infectivity of ISP-1 treated or untreated virus particles on the two target cell types after 
the cells had been ISP-1 treated.  Our data indicates that treating target cells with even 
low doses of ISP-1 causes a significant decrease in infection for all virus samples.  
Furthermore, the extent of inhibition of infection was higher for HeLa cells after ISP-1 
treatment than for NIH 3T3 cells, indicating that sphingolipids in HeLa cell membranes is 
critical for virus fusion.   
 Previous studies that have investigated the role of glycosphingolipids in virus 
fusion and entry have concentrated their efforts on altering the composition of the target 
cell membrane.  For example, Rawat et al showed that depletion of glycosphingolipids 
using PPMP (inhibitor of UDP: glycosyl transferase) from Sup-T1 cells (a suspension T 
cell line expressing low levels of CD4 and CXCR4) blocked HIV-1 envelope mediated 
fusion (17).  Interestingly, similar studies using the GM95 cell line, which expresses high 
levels of the HIV -1 receptors, showed no significant effect in the absence of 
glycosphingolipids (6).   
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 These observations have lead to the hypothesis that glycosphingolipids may 
facilitate the recruitment of receptors on the target membrane to the fusion site.  
Therefore, in cells with high levels of receptor expression, fusion is not likely to be limited 
by the need to recruit receptors to the site of virus entry, and fusion is likely to occur 
even if there is a local depletion in the number of glycosphingolipids present in the 
membrane of the cell.  Interestingly, NIH 3T3 cells express high levels of the Pit-2 
receptor proteins versus the expression in HeLa cells (7, 12).  These studies have 
investigated the importance of glycosphingolipids in the target membrane for virus 
fusion, however, our study we observe that for adequate fusion to occur, sphingolipids 
must also be present in the virus particle lipid bilayer, possibly facilitating the movement 
of virus envelope proteins such that the multivalent binding that is required for virus 
fusion can occur.  Altogether, our data suggests that depleting glycosphingolipids from 
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ALTERATION OF VIRAL LIPID COMPOSITION BY FUMONISIN INCREASES 
RETROVIRAL INFECTIVITY AND REDUCES VIRUS BUDDING 
 
4.1 Abstract 
 The lipids of enveloped viruses play an important role in viral morphogenesis and 
infectivity.  These lipids are derived from host cell membranes during virus budding, 
which has been shown to occur in regions of the host cell enriched in cholesterol and 
sphingomyelin.  In this study, we use the fungal endotoxin, fumonisin B-1 (FB-1), to 
inhibit sphingolipid synthesis in virus producer cells.  We examine the effect on the lipid 
composition of virus producing cells and the virus particles produced from them.   Our 
results suggest that the virus lipid composition can be significantly altered by FB-1 
treatment and that this treatment increases the specific infectivity of virus particles by 
affecting their ability to fuse with the target cell membrane.   
 
4.2 Introduction 
  Retrovirus particles are composed of nucleic acids surrounded by a protein shell 
that is further protected by a lipid membrane bilayer.  It is suggested that viruses acquire 
signaling proteins and lipids during the budding process and that these proteins and 
lipids play a significant role in virus attachment, fusion, and entry (7, 16).   Retroviral 
infection is a multistep process that begins with adsorption of the virus particle to the cell 
surface (6).  Amphotropic Moloney leukemia virus particles are known to initiate infection 
after engagement between the viral envelope protein and the receptors at the cell 
membrane.  This interaction induces conformational changes in the envelope receptor 
proteins and ultimately results in the mixing of the viral lipids with the host cell 
membrane lipids.   
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 The first point of contact that a virus makes with the host is with its lipid envelope, 
which consists of viral envelope lipids and proteins.  Accumulating evidence suggests 
that lipids within the viral membrane are not incorporated randomly, and are heavily 
enriched in cholesterol and sphingomyelin (SM), possibly because retroviruses bud from 
specialized sites within the plasma membrane, called lipid rafts (15).  The budding and 
assembly of several enveloped viruses has been shown to occur selectively from lipid 
rafts on the surface of infected cells (7, 13, 16, 23).  For instance, it has been reported 
that the lipid bilayer of the human immunodeficiency virus (HIV-1) contains a high 
concentration of cholesterol, sphingomyelin and proteins that are known to be 
associated with lipid raft domains (2, 4, 18).   
 Many groups have also shown that sphingolipids in the target cell membrane are 
important for virus fusion and entry.  An inhibitor in the synthesis of glycosphingolipids, 
UDP: glucosyl transferase (PPMP) has been widely used to study the role of plasma 
membrane sphingolipids (18).  Studies conducted by Hug et al have found that treating 
target cells with PPMP down regulated the production of glycosphingolipids in the target 
cells and blocked HIV-1 entry and receptor mediated fusion in various cell lines 
expressing the HIV-1 receptors (8).  Furthermore, Chieco-Bianchi et al have shown that 
blocking the synthesis of glycosphingolipids in target cells using L-cycloserine, an 
inhibitor of serine palmitoyltransferase, interferes with HIV-1 infection and replication in 
CEM cells, a CD4+ T-lymphocyte cell line (5).    
 Based on these findings, we hypothesized that altering the concentration of 
glycosphingolipids in virus producer cells will affect the lipid composition of viruses they 
produce, and by studying the function of these viruses, insights will be gained into the 
role sphingolipids play in the virus lifecycle.  To test this hypothesis, we treated the 
stably transfected cell line, TelceB6 cells, with fumonisin B-1 (FB-1).  FB-1 is a potent 
inhibitor of de novo sphingolipid biosynthesis that interferes with the formation of lipid 
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rafts (2).  In this study, we investigated the effect of altering the lipid content of virus 
producing cells on virus production and budding, and the effect of altering the lipid 
composition of virus particles on their ability to bind, fuse, and infect target cells. 
 
4.3 Material and Methods 
 Chemicals and Antibodies.  Fumonisin B-1 was obtained from Biomol 
(Philadelphia, PA). Glutaraldehyde, and 1,5-dimethyl-1,5-diazaundecamethylene 
polymethobromide (Polybrene, PB) were from Sigma Chemical Co. (St. Louis, MO). 
Hydrogen peroxide 30%, and polyoxyethylene 20-sorbitan monolaurate (Tween 20) 
were from Fisher Scientific (Fair Lawn, NJ). Centrifugation filters to concentrate and 
purify virus stock were obtained from Millipore Corporation (Billerica, MA).  Non-fat dry 
milk (blotting grade) was from Bio-Rad Laboratories (Hercules, CA). o-phenylenediamine 
dihydrochloride (OPD) was from Pierce (Rockford, IL). 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal) was from Denville Scientific, Inc. (Metuchen, NJ). Mouse anti-
p30 and mouse anti-gp70 antibodies were purified from the supernatant of the CRL-
1219 (ATCC, Rockville, MD) and the 83A25 [NL 37] hybridoma cell lines respectively, 
following standard procedures [NL 38]. The goat polyclonal anti-p30 antibody (78S221) 
and the goat polyclonal anti-gp70 (79S834) were from Quality Biotech (Camden, NJ). 
The horseradish peroxidase conjugated rabbit anti-goat immunoglobulin G polyclonal 
antibody was from Zymed Laboratories (South San Francisco, CA).   
 Cell Culture.  NIH 3T3 mouse fibroblast were cultured in Dulbecco's modified 
Eagle's medium (DMEM; Hyclone Labs Inc., Logan, UT) with 10% bovine calf serum 
(Hyclone Labs Inc.), 100 U/mL of penicillin, and 100 µg/mL of streptomycin (Hyclone 
Labs Inc.) (DMEM/BCS).  HeLa cells (human cervical kidney, ATCC) and 293T/17 cells 
(human embryonic kidney epithelial) were cultured in Dulbecco’s modified Eagle’s 
medium (Hyclone Labs Inc., Logan, UT) with 10% fetal bovine serum (Hyclone Labs 
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Inc.), 100 U/mL of penicillin and 100 µg/mL of streptomycin (DMEM/FBS).  TELCeB6-A 
(TE671 (human rhabdomyosarcoma) cells stably transfected to express lacZ, Mo-
MLVgagpol (12) and the amphotropic envelope glycoprotein (9) were cultured in DMEM, 
10% fetal bovine serum (Hyclone Labs, Inc.), 100 U/mL of penicillin, and 100 mg/mL of 
streptomycin (DMEM/FBS). 
 Fumonisin B-1 treatment.  For all experiments using fumonisin B-1, Telceb6-A 
cells were incubated with the indicated concentration of fumonisin B-1 for 24 h at 37 ºC 
in DMEM/FBS or DMEM/BCS, depending on the cell type to be transduced.   
 Lipid analysis of virus particles and cells.   Stably transfected virus producing 
cells, Telceb6-2A, and their parent cell line, Te671 which does not produce viruses, were 
used for lipid analysis.  Cells were grown to confluence in T175 flasks in DMEM/FBS.   
Telceb6-2A cells were then either treated with 0 µM or 50 µM fumonisin B-1.   Te671 
cells were not treated with fumonisin B-1.  For three days at every 24 hrs, cell 
supernatant was collected, filter sterilized (0.45 µm), and then frozen (-80 °C) for later 
use.  Harvested media was replaced with media either containing 0 µM or 50 µM 
fumonisin B-1.  As a control for lipids present in conditioned culture medium from cells 
not producing virus particles, the supernatant of untreated Te671 cells was similarly 
harvested each day for 3 days.  On the third day after harvest, the cells were put on ice 
and washed twice with cold phosphate buffered saline (PBS).  The cells were then lifted 
from the flask using a cell scraper, resuspended in PBS, counted using trypan blue and 
aliquoted in 13 x 100mm screw-capped, borosilicate glass test tubes at 107 cells per 
tube.  The cells were then centrifuged at 800 x g at 4 ºC and the pellet was stored at -20 
°C.    
 The filtered supernatant samples were concentrated using centrifugation filters 
from Millipore Corporation (Billerica, MA).   A concentrated volume of 1.5 mL to 2 mL 
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was obtained.  The total volume was brought to 7 mL in DMEM/FBS for each sample 
and applied on top of a 2 mL 20% sucrose solution.  The virus particles were then 
pelleted by centrifugation at 30,000 rpm in a Beckman SW41 rotor for 2 h at 4 ºC.  The 
supernatant was gently aspirated, the pellet was resuspended in 400 µL PBS and the 
protein content quantified using the Coomassie Plus-200 protein assay reagent.  The 
samples were stored in 13 x 100mm screw-capped, borosilicate glass test tubes with 
TeXon caps and used for sphingolipid analysis.   
 The sphingolipid analyses were conducted by liquid chromatography (LC) and 
electrospray tandem mass spectrometry using a PE Sciex API 3000 triple quadrupole 
mass spectrometer equipped with a turbo ion-spray source, as described previously (AM 
methods).  Internal standards for the mass spectrometric analyses were obtained from 
Avanti Polar Lipids (Alabaster, AL); these were C12-ceramide (N-dodecanoyl-
sphingosine, d18:1/12:0), C12-glucosylceramide, and C12-sphingomyelin.  Protocol 
adapted from Merrill et al. Methods.  36: 207-224 (2005).   
 Cells and virus samples in the borosilicate glass test tubes were mixed with 
0.5ml of methanol then 0.25ml of chloroform and the internal standards.  The internal 
standards were prepared as a working stock in methanol and chloroform (2:1 v/v) such 
that small volumes can be added to each test tube.  In general, the internal standard 
mixture is prepared to deliver 0.5 nmol of each of the following (per sample): ceramide 
(d18:1/12:0-Cer), sphingomyelin (d18:1/12:0-SM), glucosylceramide (d18:1/12:0-
GlcCer), and lactosylceramide (d18:1/12:0-LacCer) (note that all have a 12-carbon fatty 
acid side chain), and C17-sphingosine, C17-sphinganine, C17-sphingosine 1-phosphate, 
and C17-sphinganine 1-phosphate (the C17-chain length was not found in most 
samples, and was verified for each new type of sample that was analyzed). All of these 
are available from Avanti Polar Lipids (Alabaster, AL).   The test tubes were then 
sonicated until they appeared evenly dispersed, then incubated overnight at 48 °C in a 
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heating block.  The samples were then cooled to room temperature, 75 µL 1M KOH in 
methanol was added, sonicated, and incubated for 2 h at 37 °C.   These steps remove 
most of the interfering glycerolipids, in particular phosphatidylcholines that can mask 
sphingomyelins in a simple MS scan.   
 The samples were cooled to room temperature and half of the volume was 
transferred to a new test tube. This portion (named Extract A) was used for separation of 
the more polar sphingolipids by reverse-phase LC.  The solvent was removed from the 
samples using a Speed Vac-type concentrator (ThermoSavant), and re-dissolved in the 
reverse-phase LC solvent.  To the half of the extract that remained in the original test 
tube, 3 µL of glacial acetic acid was added to bring the pH near neutral, then 1 mL of 
chloroform and 2 mL of water was added, sample was vortexed, and centrifuged to 
separate the phases.  The upper layer was carefully removed using a Pasteur pipette 
(discard), leaving the interface (with water).  The solvent was then evaporated from the 
lower layer (named Extract B) using a Speed Vac-type concentrator (ThermoSavant), 
and re-dissolved in the normal-phase LC solvent. 
 Protein assay.  To quantify the amount of protein in purified virus stocks after 
filtration, concentration and sucrose-cushion ultracentrifugation, samples were analyzed 
with the Coomassie Plus-200 Protein Assay as per the manufacturer’s protocol.  Optical 
density was measured using an absorbance plate reader (Pierce, Rockford, IL) and 
bovine serum albumin was used to create standards.   
 Cell viability assay.  Ten microliters per well of MTT solution (100 mg of MTT in 
1 mL of PBS) were added per well to cells in a 96-well plate. The plate was incubated for 
4 hours at 37°C, then 150 µL of 10% sodium dodecyl sulfate (SDS) was added per well 
and the plate incubated overnight at 37oC.  The optical density at 570 nm was measured 
using an absorbance plate reader and the non-specific background at 650nm 
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subtracted. Values for replicate wells without cells were subtracted as background. 
Values for each point are the average of triplicate wells. 
 Virus Production.  To generate retrovirus particles, TELCeB6-A cells were 
grown to confluence in T175 tissue culture flasks, and then incubated for 24 h with 20 
mL of DMEM/FBS. The virus-laden tissue culture medium was harvested, filter-sterilized 
(0.45 µm), then frozen (-80 °C) for later use.   
 Diluted Titer Assay.  Ten-fold serial dilutions of lacZ virus stock were made in 
DMEM/BCS for NIH 3T3 transduction or in DMEM/FBS for HeLa transduction and were 
supplemented with Polybrene (8 µg/mL). A 1-mL amount per well was used to transduce 
NIH 3T3 cells or HeLa cells that had been seeded (5 x 104 per well or 8 x 104 per well, 
respectively) the previous day in a 12-well plate. Two days after the start of the 
transduction, the cells were fixed and stained for β-galactosidase activity with X-Gal. 
Colonies of lacZ+ cells (typically in clusters of 2, 4, or 8 blue cells) were counted with the 
aid of a dissecting microscope. At appropriate dilutions of the virus stock, the clusters of 
blue cells were sufficiently spread over the dish such that each cluster arose from a 
single transduction event.  
   Virus stability.  To determine virus particle stability, retrovirus (100 µL) 
produced from fumonisin B-1 treated or untreated cells were incubated at 37 °C for 0 hr 
to 24 hrs.  At indicated time points, a small aliquot was collected and stored (-80 °C) for 
later use.  These aliquots were then later used to transduce NIH 3T3 to determine virus 
activity.   
  Virus binding assay.  To determine if fumonisin B-1 treatment altered virus 
binding, we incubated virus produced from varying doses of fumonisin B-1 with NIH 3T3 
cells and HeLa cells.  NIH 3T3 or HeLa cells were plated to confluence in 6 well plates.  
The next day virus supernatant was applied to cells and incubated at 4 °C for 2 hrs.  The 
cells were washed twice with cold PBS, lifted from the wells using a cell scraper, 
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centrifuged (800 x g for 5 min) and the pellet resuspended in lysis buffer.  Cell lysis 
samples were then used to quantify virus protein using the p30 ELISA.   
 Production of nef-luc laz retrovirus.  Telceb6-A cells were plated at 
approximately 80% confluency in 10-cm tissue culture dishes.  The cells were 
transfected with 8 µg of pcDNA3-Nef-luc (kind gift of Robert Davey), diluted in 1.5 mL of 
DMEM, mixed with a solution of 1.5 mL of DMEM and 40 µL of Lipofectamine 2000 
reagent (Invitrogen Life Technologies, Carlsbad, CA) and then added to the cells. The 
medium was replaced 6 hours later and 18 hours later with 10 mL of DMEM/FBS. 
Twenty four hours later the supernatant was removed from the cells and replaced with 
media containing varying concentrations of fumonisin B-1.  After 24 hrs of treatment, the 
virus-laden cell culture supernatant was harvested, filter sterilized (0.45-µm) and frozen 
(-80°C) for later use.  Virus capsid protein was quantified using p30 ELISA.      
 Virus Fusion assay.  NIH 3T3 and HeLa cells were trypsinzed, counted and 
pelleted in 1.5 mL tubes such that each pellet contained 1 x 105 cells.  This protocol is 
adapted from Saeed et al (20).   The cells were resuspended in 100 µL containing equal 
amount of virus protein (p30).  Virus and cells were incubated at 37 °C for 2 hrs on a 
rotating platform.  To remove virus particles that had not fused with the cell membrane, 
the cells were pelleted by centrifugation at  800 x g for 5 min, supernatant discarded, 
and the cell pellet washed twice in DMEM.  The final cell pellet was resuspended in 0.1 
mL of Luciferase Assay Buffer (Promega) and the luciferase activity was measured 
using a Turner Biosystems Modulus Microplate reader and expressed as relative 
luciferase units.   
 Beta-galactosidase (β-gal) transduction assay. Five thousand NIH 3T3 murine 
fibroblasts or eight thousand HeLa cells suspended in 100 µL of medium were plated in 
each well of a 96-well flat-bottomed tissue culture dish with a low-evaporation lid (Costar 
Corp., Cambridge, MA) (21). The next day, the medium was removed and 100 µL of the 
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virus-containing solution was added to each well. Two days after transduction, the 
medium was removed and the cells washed once with 100 µL of PBS containing 1mM 
MgCl2. After removal of the wash solution, 50 µL of lysis buffer (PBS with 1mM MgCl2 
and 0.5% Igepal) were added to each well, and the plate incubated at 37 °C. After 30 
min, 50 µL of lysis buffer with 6 mM ONPG was warmed to 37 °C, added to each well, 
and the plate incubated at 37°C for 5 to 60 min until a visible yellow color was obtained. 
The reactions were halted by the addition of 20 µL per well of stop buffer (1M Na2CO3). 
The optical density at 420 nm (OD420) was measured using an absorbance plate reader 
(Molecular Devices, Menlo Park, CA) and the non-specific background at 650 nm 
subtracted. Values for replicate wells without virus were subtracted as background. 
Values for each point are the averages of at least triplicate wells. 
 ELISA for p30 and gp70.  The concentration of virus capsid protein and 
envelope protein, p30 and gp70 respectively, were quantified using a previously 
described enzyme-linked immunosorbent assay (ELISA) (10). Briefly, ELISA plates 
(Nunc immuno Maxisorp 96-well plates, Nalgen Nunc International, Rochester, NY) were 
coated overnight at 4 °C with 10 µg/mL of mouse anti-p30 antibody or mouse anti-gp70 
antibody (100 µL/well) in PBS. The next day, the antibody solution was removed and 
blocking buffer (PBS, 0.05% Tween-20, 5% non-fat milk) was added (200 µL/well) for 2 h 
at 37°C to block non-specific binding sites. Virus particles were lysed using 0.5% Triton-
X to expose the p30 antigen, then added to the ELISA plate (100 µL/well) and incubated 
for 1 h at 37 °C. Bound p30 and gp70 were sandwiched by either the addition of the goat 
polyclonal anti-p30 antibody diluted 1:1000 or goat polyclonal anti-gp70 antibody diluted 
1:300 in blocking buffer for 1 h at 37 °C (10), respectively. The horseradish peroxidase 
conjugated polyclonal rabbit anti-goat immunoglobulin G was diluted 1:5000 in blocking 
buffer and added to the ELISA plate (100 µL/well) for 1 h at 37 °C to enable detection 
and quantitation of the p30 or gp70 antigen. The plates were developed for 5 min using 
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hydrogen peroxide (H2O2) and OPD (100 µg/well) from a solution of 3 mg of OPD and 3 
µl H2O2 in 7.5 mL of substrate buffer (24 mM citric acid-monohydrate, 51 mM Na2HPO4-
7H20, pH 5.0).  Sulfuric acid (8 N, 50 µL/well) was used to stop the reaction, the optical 
density at 490 nm was measured using an absorbance plate reader, and the non-
specific background at 650 nm was subtracted. Values for replicate wells without virus 
were subtracted as background. 
 Virus Budding Assay.  Telceb6-A cells were plated to confluence in 6-well 
tissue culture plates and cultured in DMEM/FBS media.  The next day, the cells were 
treated with 50 µM fumonisin B-1 or left untreated.  The next day, the cell culture media 
was replaced with media containing 50 µM fumonisin B-1 or 0 µM fumonisin B-1.  After 
24 hours the supernatant was harvested, filter-sterilized (0.45 µm), then frozen (-80 °C) 
for later use.  An aliquot of the supernatant (STOCK) was collected and stored 
separately.  After harvesting the supernatant the cells were washed with cold PBS and 
removed from the tissue culture plates using a cell scraper.  The cells were then pelleted 
at  800 x g for 5 min and resuspended in 0.5% Triton-X to lyse the cells and expose the 
p30 antigen inside the cells.  These cell lyses samples were used to measure p30 inside 
the cells using the p30 ELISA.  Also, to measure pelletable virus, the virus stored 
supernatant was mixed with 80 µg/mL of Polybrene and chondroitin sulfate-C, incubated 
for 20 min at 37 ºC and centrifuged at 6000 x g for 20 min.  The supernatant was 
collected and p30 in the samples was measured to determine the amount of p30 that 
could not be pelleted (SN, supernatant).  The pellet was resuspended in PBS and p30 
was measured to determine the amount of pelletable p30 (PELLET).     
 Statistical Analysis.  Data are summarized as the mean ± one standard 
deviation for triplicate samples.  Statistical analysis was performed using one-way 
analysis of variance for repeated measurements of the same variable.  The Tukey 
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multiple comparison test was used to conduct pairwise comparisons between means.  
Differences at p < 0.05 were considered statistically significant. 
4.4 Results 
 During virus budding, viruses acquire a lipid bilayer composed of signaling 
proteins and host lipids, both of which play a significant role in virus attachment, fusion 
and entry.   The role of the envelope proteins in the retrovirus lifecycle has been 
extensively studied.  Much less is known about the role of specific lipids in virus binding 
and infection.  Here we studied the effect of blocking de novo sphingolipid biosynthesis 
on virus function by treatment of virus producing cells with fumonisin (FB-1), a potent 
inhibitor of serine palmitoyl-CoA transferase (SPT) which is a rate limiting enzyme in the 
biosynthesis of sphingolipids (Figure 4.1) (Hojjati et al 2005).   
 As a first step toward investigating the effects of altering sphingolipid synthesis in 
virus producer cells on the lipid composition of the virus lipid bilayer, we treated TelCeB6 
cells with 50 µM FB-1 (added from a 1 mM stock solution in phosphate-buffered saline) 
for 24 hours, or left them untreated, harvested the virus supernatant and analyzed the 
lipid composition of the cells and virus particles using mass spectrometry (Figure 4.2 A-
C).  After the virus producer cells were treated with FB-1, they were washed with cold 
PBS three times, counted, pelleted and stored at -20oC.  The TelCeB6 parent cell line, 
Te671, the parent cell line of Telceb6, was used as a control for determining how many 
lipids that are not associated with viruses are present in medium conditioned by the 
cells.  Conditioned medium that we had previously collected from Te671, TelCeB6 and 
TelCeB6 cells treated with 50 µM FB-1 was thawed, concentrated, pelleted and purified 
two times with a 20% sucrose cushion.  Protein concentration in the pelleted supernatant 
was quantified and aliquots of the sample, each of which contained equal amounts of 
protein, were analyzed for lipid content by mass spectrometry.  Lipids were extracted 


























Figure 4.1. The pathway of de novo sphingolipid biosynthesis and sites of action 











































Figure 4.2 (A). Mass spectrometry analysis of ceramide present in virus producer 
cells.  Stably transfected virus producing cells, Telceb6-2A, and their parent cell line, 
Te671 which does not produce viruses, were used for lipid analysis.  Cells were grown 
to confluence in T175 flasks in DMEM/FBS.   Telceb6-2A cells were then either treated 
with 0 µM or 50 µM FB-1.   Te671 cells were not treated with FB-1.  Every 24 hrs, for 72 
hours, cell supernatant was collected, filter sterilized (0.45 µm), then frozen (-80 °C).  
Harvested media was replaced with media either containing 0 µM or 50 µM FB-1.  As a 
control for lipids present in conditioned culture medium from cells not producing virus 
particles, the supernatant of untreated Te671 cells was similarly harvested each day for 
3 days.  On the third day after harvest, the cells were put on ice and washed twice with 
cold phosphate buffered saline (PBS).  Cells were then lifted from the flask using a cell 
scraper, resuspended in PBS, counted and aliquoted in borosilicate glass test tubes at 
107 cells per tube and pelleted centrifuged at 800 x g at 4 ºC.     (*) denotes statistically 






































Figure 4.2 (B). Mass spectrometry analysis of glucosylceramide present in virus 
producer cells.  Stably transfected virus producing cells, Telceb6-2A, and their parent 
cell line, Te671 which does not produce viruses, were used for lipid analysis.  Cells were 
grown to confluence in T175 flasks in DMEM/FBS.   Telceb6-2A cells were then either 
treated with 0 µM or 50 µM FB-1.   Te671 cells were not treated with FB-1.  Every 24 
hrs, for 72 hours, cell supernatant was collected, filter sterilized (0.45 µm), then frozen (-
80 °C).  Harvested media was replaced with media either containing 0 µM or 50 µM FB-
1.  As a control for lipids present in conditioned culture medium from cells not producing 
virus particles, the supernatant of untreated Te671 cells was similarly harvested each 
day for 3 days.  On the third day after harvest, the cells were put on ice and washed 
twice with cold phosphate buffered saline (PBS).  Cells were then lifted from the flask 
using a cell scraper, resuspended in PBS, counted and aliquoted in borosilicate glass 
test tubes at 107 cells per tube and pelleted centrifuged at 800 x g at 4 ºC.     (*) denotes 











































Figure 4.2 (C). Mass spectrometry analysis of sphingomyelin present in virus 
producer cells.  Stably transfected virus producing cells, Telceb6-2A, and their parent 
cell line, Te671 which does not produce viruses, were used for lipid analysis.  Cells were 
grown to confluence in T175 flasks in DMEM/FBS.   Telceb6-2A cells were then either 
treated with 0 µM or 50 µM FB-1.   Te671 cells were not treated with FB-1.  Every 24 
hrs, for 72 hours, cell supernatant was collected, filter sterilized (0.45 µm), then frozen (-
80 °C).  Harvested media was replaced with media either containing 0 µM or 50 µM FB-
1.  As a control for lipids present in conditioned culture medium from cells not producing 
virus particles, the supernatant of untreated Te671 cells was similarly harvested each 
day for 3 days.  On the third day after harvest, the cells were put on ice and washed 
twice with cold phosphate buffered saline (PBS).  Cells were then lifted from the flask 
using a cell scraper, resuspended in PBS, counted and aliquoted in borosilicate glass 
test tubes at 107 cells per tube and pelleted centrifuged at 800 x g at 4 ºC.     (*) denotes 



















































Figure 4.2 (D). Mass spectrometry analysis of ceramide in virus particles. Virus 
producer cells were treated as indicated in Figure 4.2 (A-C).  The filtered supernatant 
samples collected from these cells were concentrated using centrifugation filters from 
Millipore Corporation (Billerica, MA).   A concentrated volume of 1.5 mL to 2 mL was 
obtained.  The total volume was brought to 7 mL in DMEM/FBS for each sample and 
applied on top of a 2 mL 20% sucrose solution.  The virus particles were then pelleted by 
centrifugation at 30,000 rpm in a Beckman SW41 rotor for 2 h at 4 ºC.  The supernatant 
was gently aspirated, the pellet was resuspended in 400 µL PBS and the protein content 
quantified using the Coomassie Plus-200 protein assay reagent.  The samples were 
stored in 13 x 100mm screw-capped, borosilicate glass test tubes with teflon caps and 
used for sphingolipid analysis.  (*) denotes statistically significant differences between 








































Figure 4.2 (E). Mass spectrometry analysis of glucosylceramide in virus particles.  
Virus producer cells were treated as indicated in Figure 4.2 (A-C).  The filtered 
supernatant samples were concentrated using centrifugation filters from Millipore 
Corporation (Billerica, MA).   A concentrated volume of 1.5 mL to 2 mL was obtained.  
The total volume was brought to 7 mL in DMEM/FBS for each sample and applied on top 
of a 2 mL 20% sucrose solution.  The virus particles were then pelleted by centrifugation 
at 30,000 rpm in a Beckman SW41 rotor for 2 h at 4 ºC.  The supernatant was gently 
aspirated, the pellet was resuspended in 400 µL PBS and the protein content quantified 
using the Coomassie Plus-200 protein assay reagent.  The samples were stored in 13 x 
100mm screw-capped, borosilicate glass test tubes with teflon caps and used for 
sphingolipid analysis.  (*) denotes statistically significant differences between treated 








































Figure 4.2 (F). Mass spectrometry analysis of sphingomyelin in virus particles. 
Virus producer cells were treated as indicated in Figure 4.2 (A-C).  The filtered 
supernatant samples were concentrated using centrifugation filters from Millipore 
Corporation (Billerica, MA).   A concentrated volume of 1.5 mL to 2 mL was obtained.  
The total volume was brought to 7 mL in DMEM/FBS for each sample and applied on top 
of a 2 mL 20% sucrose solution.  The virus particles were then pelleted by centrifugation 
at 30,000 rpm in a Beckman SW41 rotor for 2 h at 4 ºC.  The supernatant was gently 
aspirated, the pellet was resuspended in 400 µL PBS and the protein content quantified 
using the Coomassie Plus-200 protein assay reagent.  The samples were stored in 13 x 
100mm screw-capped, borosilicate glass test tubes with teflon caps and used for 

























products in the lipid synthesis pathway affected by FB-1: ceramide, glycosylceramide 
and sphingomyelin (Figure 4.2 D-F).  Cells treated with FB-1 and their resulting 
conditioned medium showed a marked decrease in the concentration of all three 
sphingolipids species as compared to untreated TelCeB6 cells.  Our results show that 
significant decreases in all three subspecies of lipids occurs after 24 hours of 50 µM FB-
1 treatment, suggesting that the toxin is active and elicits the expected effects.  Also, 
since the accumulation of sphingolipid metabolites can affect cell function, we measured 
the cell viability of the virus producing cells as well as of the target cells (Figure 4.3).  
Our results suggest that FB-1 was not cytotoxic at the tested doses and that the 
decrease in virus titer was not due to decreased number of cells.    
 Next, to determine the effect of FB-1 treatment on virus production and infection, 
we treated Telceb6 cells with a range of concentrations, 0 to 100 µM of FB-1 and 
harvested the virus supernatant after 24 hours.  We quantified by ELISA the amount of 
virus that was produced by the treated cells (Figure 4.4 A).   Interestingly, we found that 
FB-1 treatment decreased the amount of virus produced from the virus producer cells.  
To further investigate the increase in virus infectivity, we measured the extent of 
envelope incorporation into virus particles after FB-1 treatment (Figure 4.4 B-C).  
Interestingly, our results suggest that although there is a decrease in virus capsid protein 
(p30) production, the amount of virus envelope protein in each virus particle actually 
increases. 
 Although we observed a decrease in p30 concentration in the virus supernatant, 
it was unclear whether this was due to a decrease in p30 production by the cell, or if p30 
production per cell remained constant and the decrease in p30 was due to less budding 
from the producer cells.  Therefore, we measured the amount of p30 protein produced 

































Figure 4.3 Effect of varying doses of FB-1 treatment on cell viability.  Virus 
producer cell line (TelCeb6) and target cells (NIH 3T3 and HeLa cells) were plated at a 
density of 10,000 cells per well and 5,000 cells per well in 96-well plates.  The next day, 
the cells were treated with varying doses of FB-1 as indicated.  TelCeb6 were assayed 
for cell viability after 24 hours of FB-1 treatment and NIH 3T3 and HeLa cells were 
assayed after 48 hours of treatment.  After 24 or 48 hours, 10 µL per well of MTT 
solution (100 mg of MTT in 1 mL of PBS) were added per well to cells in a 96-well plate. 
The plate was incubated for 4 hours at 37°C, then 150 µL of 10% SDS were added per 
well and the plate incubated overnight. The optical density at 570 nm was measured 
using an absorbance plate reader and the non-specific background at 650nm 
subtracted. Values for replicate wells without cells were subtracted as background. 




































Figure 4.4 (A). Fumonisin treatment affects virus production.   TelCeB6, were plated 
at 240, 000 cells per well of a 6-well plate and grown to confluency.  The next day, cell 
culture media was removed and replaced with media containing varying doses of FB-1 
as indicated.  After 24 hours, the conditioned cell media was collected and filter sterilized 
(0.45 µm).   The concentration of virus in the supernatant after treating virus producer 
cells with different doses of FB-1 was determined using the p30 ELISA.  Each point 




































Figure 4.4 (B). Effect of fumonisin treatment on gp70 incorporation.   Virus 
producer cells, TelCeB6, were plated at 240, 000 cells per well of a 6-well plate and 
grown to confluency.  The next day, cell culture media was removed and replaced with 
media containing varying doses of FB-1 as indicated.  After 24 hours, the conditioned 
cell media was collected and filter sterilized (0.45 µm).   The concentration of virus in the 
supernatant after treating virus producer cells with different doses of FB-1 was 
determined using the gp70 ELISA.  Each point shows the mean ± standard deviation of 








































Figure 4.4 (C). Amount of gp70 proteins per p30 virus capsid protein.  The gp70 
virus fusion protein was normalized to the concentration of virus protein p30 (part A and 
B).  TelCeB6, were plated at 240, 000 cells per well of a 6-well plate and grown to 
confluency.  The next day, cell culture media was removed and replaced with media 
containing varying doses of FB-1 as indicated.  After 24 hours, the conditioned cell 
media was collected and filter sterilized (0.45 µm).   The concentration of virus in the 
supernatant after treating virus producer cells with different doses of FB-1 was 





































Figure 4.5. Fumonisin treatment affects the ability of virus to bud from target cell 
membranes.  Telceb6-A cells were plated to confluence in 6-well tissue culture plates 
and cultured in DMEM/FBS media.  The next day, the cells were treated with 50 µM 
fumonisin B-1 or left untreated.  The next day, the cell culture media was replaced with 
media containing 50 µM fumonisin B-1 or 0 µM fumonisin B-1.  After 24 hours the 
supernatant was harvested, filter-sterilized (0.45 µm), then frozen (-80 °C) for later use.  
An aliquot of the supernatant (STOCK) was collected and stored separately.  After 
harvesting the supernatant the cells were washed with cold PBS and removed from the 
tissue culture plates using a cell scraper.  The cells were then pelleted at  800 x g for 5 
min and resuspended in 0.5% Triton-X to lyse the cells and expose the p30 antigen 
inside the cells.  These cell lyses samples were used to measure p30 inside the cells 
using the p30 ELISA.  Also, to measure pelletable virus, the virus stored supernatant 
was mixed with 80 µg/mL of Polybrene and chondroitin sulfate-C, incubated for 20 min at 
37 ºC and centrifuged at 6000 x g for 20 min.  The supernatant was collected and p30 in 
the samples was measured to determine the amount of unpellatable p30 (SN, 
supernatant).  The pellet was resuspended in PBS and p30 was measured to determine 
the amount of pelletable p30 (PELLET).  (*) denotes statistically significant differences 
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and treated with FB-1 for 48 hours.  Then virus supernatant was harvested (STOCK), 
centrifuged and pelleted using polybrene and chondroitin sulfate – C.  The supernatant 
was collected (SN) and the pellet (PELLET) was resuspended in PBS and used in the 
p30 ELISA.  The cells were washed with cold PBS, and removed from the tissue culture 
plates using a cell scraper.  The cells were then centrifuged, counted and lyzed to 
measure p30 protein.  From these studies, we found that although virus producer cells 
contained similar amounts of p30 protein after FB-1 treatment, the viral supernatant had 
significant lower levels of p30.  These results suggest that viral protein p30 is being 
produced inside the cells but lipid biosynthesis is interfering with its budding and release 
from the cell membrane. 
 To determine the effect of FB-1 treatment on virus infectivity, we treated a virus 
producing cell line (TelCeB6) with FB-1 (0 to 100 µM) and harvested the virus 
supernatant after 24 hours. We measured virus titer on NIH 3T3 cells and HeLa cells 
using the β-gal assay (Figure 4.6 A-B).   Our results suggest that the virus particles 
produced from the treatment were more fusogenic than particles produced from 
untreated cell.  Specifically, we found that the virus titer increased by 2-6 fold depending 
on the dose of the treatment and the cell type.  To determine whether the increase in 
virus infectivity was due to the production of more stable virus particles, we incubated 
virus at 37oC for up to 24 hours, after which we used samples from different time points 
to transduce NIH 3T3 cells (Figure 4.7).  We found that there was no statistical 
difference between the half-life of FB-1 treated virus of 8.3 hours and that of the 
untreated virus 8.8 hours (p<0.05) indicating that altering lipid content in the virus lipid 
bilayer does not affect the stability of the virus particles.   
 In order to determine the mechanism by which changes in the lipid content elicit 
a change in retrovirus transduction, we investigated retrovirus binding and fusion after 




















Figure 4.6 (A). Effect on virus production and infection after treating virus 
producer cells with FB-1.    TelCeB6, were plated at 240, 000 cells per well of a 6-well 
plate and grown to confluency.  The next day, cell culture media was removed and 
replaced with media containing varying doses of FB-1 as indicated.  After 24 hours, the 
conditioned cell media was collected and concentration of p30 determined using the p30 
ELISA.  Same virus stock was used to measure titer.  NIH 3T3 cells were plated at 60 
000 cells per well and HeLa cells were plated at 80 000 cells per well of 12-well plates.  
The next day, the ten-fold serial dilutions of virus stock were made in DMEM/BCS for 
NIH 3T3 transduction or in DMEM/FBS for HeLa transduction, supplemented with 
Polybrene (8 µg/mL) and incubated with cells.  Two days after the start of the 
transduction, the cells were fixed and stained for β-galactosidase activity with X-Gal.  
Colonies were counted with the aid of a dissecting microscope. At appropriate dilutions 
of the virus stock, the clusters of blue cells were sufficiently spread over the dish such 
that each cluster arose from a single transduction event. Each point shows the mean ± 

























































































Figure 4.6 (B). Treatment of virus producer cells with FB-1 increases the titer of 
the virus produced from those cells.  Titer data shown in Figure 4.6 was normalized 
to the respective p30 concentration and are reported here as fold-increase in specific 
activity.  Virus stock was produced after various doses of FB-1 treatment of TeLceB6 
cells.  NIH 3T3 cells were plated at 60 000 cells per well and HeLa cells were plated at 
80 000 cells per well of 12-well plates.  The next day, the ten-fold serial dilutions of virus 
stock were made in DMEM/BCS for NIH 3T3 transduction or in DMEM/FBS for HeLa 
transduction, supplemented with Polybrene (8 µg/mL) and incubated with cells.  Two 
days after the start of the transduction, the cells were fixed and stained for β-
galactosidase activity with X-Gal.  Colonies were counted with the aid of a dissecting 
microscope. At appropriate dilutions of the virus stock, the clusters of blue cells were 
sufficiently spread over the dish such that each cluster arose from a single transduction 






























































Figure 4.7. Stability of virus particles is not affected by fumonisin treatment.  
TelCeb6 cells were plated at 240 000 cells per well in 6-well plates.  The next day, the 
cell culture media was supplemented with 0 or 50 µM FB-1.  After 24 hours, the virus 
supernatant was harvested and filter sterilized.  Retrovirus (100 µL) produced from FB-1 
treated or untreated virus producing cells were incubated at 37 °C for 0 hr to 24 hrs.  At 
indicated time points, a small aliquot was collected and stored (-80 °C) for later use.  








































stock to determine the linear range of virus binding so as to avoid saturating virus 
particles on the cell surface (Figure 4.8 A).  We incubated virus stock with NIH 3T3 cell 
or HeLa cells at 4 oC for 2 hours.  The cells were then washed twice with cold PBS, lysed 
and p30 concentration was quantified.  Our results revealed that even with 100% virus 
supernatant, we did not saturate the surface of target cells.  Next, we conducted this 
assay to measure the extent of binding of virus particles that had been produced after 
FB-1 treatment (Figure 4.8 B).  Our results indicated that untreated virus bound to both 
cell types to the same extent as FB-1 treated virus, suggesting that FB-1 treatment does 
not reduce binding of virus particles.  Next, we used a nef-luciferase assay to measure 
the change in virus fusion (Figure 4.9).  The pcDNA3-Nef-luc plasmid was transfected 
into virus producing cells, which were then treated with FB-1.  Interestingly we found that 
the increase in virus titer occurred due to increased virus fusiogenicity.  In both cell 
types, we observed a 2 fold increase in infection at 25 µM FB-1 and a 4 to 6-fold 
increase at 100 µM for NIH 3T3 and HeLa cells, respectively.  Altogether, this data 
suggests that depleting lipids by using FB-1 from virus particles significantly increased 
the infectivity.   
 The lipid composition of the target cell membrane is also known to be important 
for virus fusion and entry.  To determine whether altering the lipid composition of target 
cells by FB-1 treatment could affect the infectivity of virus, we incubated target cells with 
virus, either produced from FB-1 treatment or not, in the presence of various 
concentrations of FB-1 (Figure 4.10 A-B).  We then measured virus infectivity.  We found 
that in the presence of FB-1 there was no significant difference in virus infection of NIH 
3T3 cells.  Interestingly, in similar experiments with HeLa cells we found that virus 



















Figure 4.8 (A). Binding of virus particles to NIH 3T3 cells is not saturated at high 
concentrations of virus.  NIH 3T3 cells were plated to confluence in 6 well plates.  The 
next day different concentration of virus produced from TelCeB6 cells (virus producer 
cells) was incubated with NIH 3T3 cells at 4 °C for 2 hrs.  The cells were washed twice 
with cold PBS, lifted from the wells using a cell scraper, centrifuged (800 x g for 5 min) 
and the pellet resuspended in lysis buffer.  Cell lysis samples were then used to quantify 
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Figure 4.8 (B). Binding of virus particles produced from myriocin treated virus 
producer cells is not adversely affected.  NIH 3T3 or HeLa cells were plated to 
confluence in 6 well plates.  The next day virus produced after various concentrations of 
FB-1 treatment of virus producing cells, was applied to cells and incubated at 4 °C for 2 
hrs.  The cells were washed twice with cold PBS, lifted from the wells using a cell 
scraper, centrifuged (800 x g for 5 min) and the pellet resuspended in lysis buffer.  Cell 

























































Figure 4.9. Virus particles produced by FB-1 treated cells fuse more efficiently 
with target cells.   Telceb6-A cells were plated at approximately 80% confluency in 10-
cm tissue culture dishes.  The cells were transfected with 8 µg of pcDNA3-Nef-luc using 
Lipofectamine and added to the cells. The medium was replaced 6 hours later and 
replaced with DMEM/FBS. After 24 hours the supernatant was removed from the cells 
and replaced with media containing varying concentrations of FB-1.  After 24 hrs of 
treatment, the virus-laden cell culture supernatant was harvested, filter sterilized (0.45-
µm) and used to infect NIH 3T3 and HeLa cells.  NIH 3T3 and HeLa cells were 
incubated with virus at 37 °C for 2 hrs on a rotating platform.  After this, the cells were 
pelleted by centrifugation at 800 x g for 5 min, supernatant discarded, and the cell pellet 
washed twice in DMEM.  The final cell pellet was resuspended in 0.1 mL of Luciferase 
Assay Buffer (Promega) and the luciferase activity was measured using a Turner 
Biosystems Modulus Microplate reader and expressed as relative luciferase units.  This 



































































































Figure 4.10 (A). Effect on virus infection after FB-1 treatment of NIH 3T3 cells.  
Virus was produced from the treatment of Telceb6 cells with FB-1 with concentrations of 
0 µM, 25 µM and 50µM.  After 24 hours the virus was harvested and diluted in a range of 
concentrations of FB-1, as indicated, and this mixture was used to transduce NIH 3T3 
cells.  NIH 3T3 cells had been plated at 5 000 cells per well of a 96 well one day earlier.  
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Figure 4.10 (B). Effect on virus infection after FB-1 treatment of HeLa cells.  Virus 
was produced from the treatment of Telceb6 cells with FB-1 with concentrations of 0 µM, 
25 µM and 50µM.  After 24 hours the virus was harvested and diluted in a range of 
concentrations of FB-1, as indicated, and this mixture was used to transduce HeLa cells.  
HeLa cells had been plated at 8 000 cells per well of a 96 well one day earlier.  Two 
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4.5 Discussion 
 Previous studies have shown that inhibition of cholesterol synthesis in retrovirus 
producing cells or cholesterol extraction from target cells causes a significant decrease 
in virus production and infection.  To test whether altering the levels of sphingolipids has 
a significant effect on MLV production and infection, we subjected virus producer cells to 
fumonisin B-1 (FB-1) treatment.  FB-1 blocks de novo sphingolipid biosynthesis by 
inhibiting the synthesis of dihydroceramide, which is a precursor to all sphingolipid 
species, and by inhibiting the salvage pathway (19).  First, we analyzed the effect of FB-
1 treatment on the lipid composition of the cells.  We found that there was significant 
reduction in the amount of sphingolipids in the FB-1 treated cells as compared to 
untreated cells.  Specifically, reductions of 85% ceramide, 90% glucosylceramides, 60% 
sphingomyelin were observed.  Furthermore, we purified and analyzed the virus particles 
from FB-1 treated cells and found that FB-1 treated virus particles exhibited a 
significantly reduced ratio of sphingolipids as compared to virus particles produced from 
untreated cells.  Reductions of 30% in ceramides, 75% glucosylceramides, 30% 
sphingomyelin were observed for the different sphingolipids species.   Since 
sphingolipids can have severe toxicity effects on cells, we measured cell viability of virus 
producing cells and the target cells used for infectivity assays (NIH 3T3 and HeLa cells) 
after they had been treated with FB-1.  Our results indicated that cell viability was not 
affected by the treatment.   
 Next we analyzed the effect of FB-1 treatment on virus production and infection.  
Results from measuring virus capsid protein in stocks 24 hrs after FB-1 treatment 
indicate that FB-1 treatment of virus producing cells had a significant effect on virus 
production or release.  At FB-1 concentration of 50 µM, we observed 65% less 
production in virus capsid protein in the stock cultures.  Furthermore, we observed a 
significant effect on specific infectivity of virus particles produced from FB-1 treatment.  
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Virus particles produced after 50 µM FB-1 treatment showed a 2-fold increase in 
infectivity to HeLa cells and an increase of 3.6-fold infectivity in NIH 3T3 cells.  Our 
results suggest there is a dose dependant increase in virus infectivity for both cell types.   
 Changing the lipid content of virus producing cells may also affect virus stability 
retroviruses are known to be enriched in specific lipid species, the removal of which 
makes virus particles inactive (such as cholesterol) (7, 17).  For instance, depletion of 
cholesterol from virus particles or virus producing cells has shown to inactivate virus 
particles possibly by destabilizing the viral lipid bilayer (3).  Our studies indicated that 
there was no difference in virus stability after FB-1 treatment and that both, viruses 
produced from untreated and treated cells decayed at similar rates.  To further 
determine the increase in virus infectivity, we measured the effect of FB-1 treatment on 
virus binding to the target cells.  Our results indicated that there is also no significant on 
the binding of virus particles.   Lastly, we determined whether the increase in infectivity 
of virus particles occurred at the point where the virus membrane fuses with the target 
cell membrane.  The results show that virus fusion increases as the dose of FB-1 
treatments increased.  These results indicate that depleting lipids from virus particles 
increased their infectivity by altering their ability to fuse with the target cell membrane.   
 Previous studies have suggested that virus budding sites are enriched in 
sphingolipids, such as sphingomyelin, thus disrupting sphingolipids synthesis may (7, 
16).    Thus, altering the synthesis in virus producing cells may alter virus capsid 
production or the production of virus envelope proteins, gp70.  In our studies, we found 
that the production of p30 decreased as the dose of FB-1 treatment increased.  
Interestingly, the envelope protein production (gp70) increased with increasing doses of 
FB-1.  This suggests that although there were fewer virus particles in the supernatant of 
virus producing cells, the virus particles after FB-1 treatment had greater number of 
gp70 proteins than viruses produced from untreated cells.   
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 Retroviruses proteins have been shown to accumulate in intracellular vesicles, 
called multivesicular bodies (MVB) (8, 22).  It has been implied that the MLV virus 
particles bud into MVB vesicles and then MVBs release the viral content to disseminate 
the virus particles.  One theory is that viral Gag proteins, structural proteins of the viral 
nucleocapsid, are sorted directly from the Golgi where they interact with the envelope 
proteins via host cell effector proteins (such as TIP47) (1, 11).  Interestingly, an alternate 
hypothesis to this theory is that retroviral proteins such as Gag and Env, all accumulate, 
assemble and bud from the plasma membrane.  Recent studies by Jouvnet et al show 
time-lapse microscopy of HIV particles accumulating and budding from the plasma 
membrane (13, 14).  These studies also showed that interfering with the endocytosis 
pathway of infected cells blocked the accumulation of HIV proteins in MVBs but did not 
interfere with virus release, further supporting the theory that retrovirus particles bud 
from the plasma membrane.  Given our observations in the changes of virus producing 
cells after FB-1 treatment, it is possible that FB-1 treatment is interfering with the 
accumulation of viral proteins at the plasma membrane, and that although these proteins 
are produced by the cells, they are not able to bud as whole virus particles.  Therefore, 
we examined the extent of the viral capsid protein production in virus producing cells 
after FB-1 treatment.  Interestingly, our results indicated that FB-1 treatment interferes 
with the accumulation of viral proteins whether at the plasma membrane or in MVBs, and 
that although these proteins are produced by the cells, they are not able to bud as whole 
virus particles.  Altogether, these results suggest that depleting sphingolipids using FB-1 
from virus producing cells inhibits virus budding.  Also, we found that blocking 
sphingolipid synthesis in virus producing cells affects virus production and fusion.   
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CONCLUSION AND FUTURE CONSIDERATIONS 
 
5.1 Summary of results 
 In Chapter 2, we describe a new method for modifying the surfaces of retrovirus 
particles using lipid conjugates.  The lipid conjugates consisted of a hydrophobic lipid 
anchor, 1,2-Distearoyl-sn-Glycero-3-phosphoethanolamine (DSPE), attached to a 
polymer linker, poly (ethylene glycol) chain which is covalently attached to the targeting 
functional group, biotin.  These constructs, when mixed with a virus stock, associated 
with the virus surface in less than 2 hours. We used model replication-incompetent 
amphotropic retroviruses that encoded lacZ gene to investigate the characteristics of 
lipid conjugate modification containing biotin as a model cell-targeting group.  We found 
that in less than 2 hours, the number of constructs that were associated with the 
particles reached a maximum. Even though the lipid conjugates were not covalently 
bound to the viruses, 25 % dissociated from the viruses after 8 hours of incubation at 370 
C in medium that contained 10% serum. Viruses modified with biotin conjugates bound 
to streptavidin-coated plates three-fold more than unmodified viruses.  Importantly, virus 
titer experiments showed that the conjugates did not reduce the ability of the viruses to 
transduce cells.     
 In chapter 3 we investigated the use of fungal endotoxin, myriocin (ISP-1) to 
inhibit de novo sphingolipid synthesis in virus producer cells.  We examine the effect on 
the lipid composition of virus producing cells and the virus particles produced from them.   
Since sphingolipids have been implicated in a variety of pathogens to help facilitate the 
entry process, we studied the effect of altering the lipid composition of virus particles on 
virus function.  Our results suggest that the virus lipid composition can be significantly 
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altered by treating cells with ISP-1 and that these particles exhibit reduced infectivity in a 
cell-type dependant manner.  Furthermore, the lipids of enveloped viruses play an 
important role in virus viral morphogenesis and infectivity, therefore we investigated 
different steps involved in the virus infection pathway and found that virus particles 
produced from ISP-1 treated cells are less fusogenic as compared to untreated cells.  
The implications of these results to improve gene therapy vectors and anti-retroviral 
therapies are discussed.   
 In chapter 4 we determined the effect of blocking sphingolipid synthesis by using 
fumonisin B-1 (FB-1) of virus producing cells and examined the effect on virus function.  
We found culturing virus producer cells in the presence of FB-1 leads to a drastic 
decrease in the levels of ceramide, sphingomyelin and glucosyphingolipids.   Viruses 
produced with 50 µM FB-1 treatment were observed to be as stable as, and bind to the 
same extent as viruses produced from untreated cells.  Interestingly, virus from FB-1 
treatment was 4 to 6-fold more infectious at doses of 100 µM than controls virus 
particles.  Interestingly, we found that FB-1 treatment interferes with virus budding and 
release from virus producing cells.  Possible mechanisms for these observations are 
discussed.   
 
5.2 Conclusions 
 In conclusion, we found that:  
1. The surface of enveloped retroviruses can be altered with lipid 
conjugates.  The modification is able to alter virus binding without 
reducing the ability of the viruses to infect cells. 
2. Treatment of virus producer cells with ISP-1 decreased the concentration 
of sphingolipids in the lipid bilayers of the viruses they produced.  The 
infectivity of these viruses was reduced in a cell-dependant manner. 
 139 
3. The treatment of virus producer cells with fumonisin B1 decreased virus 
budding and increased the number of virus envelope proteins that were 
incorporated into the virus particles.  The infectivity and fusogenicity of 
these viruses were higher than unmodified control viruses. 
 
5.3 Future Considerations 
 In Chapter 2, we describe a novel strategy to alter the surface of virus particles 
using lipid-PEG conjugates tagged with biotin.   We found that modified virus particles 
preferentially bound to a strepavidin-coated surface as compared to unmodified viruses 
and that the modification did not adversely affect virus infectivity.  In Chapter 3 and 4 we 
investigated the role of lipids in virus binding and infection.  We found that the treatment 
of virus producing cells with pharmacological agents can alter the composition of the 
virus lipid membrane, thereby affecting the ability of the virus’ ability to fuse with cell 
membranes.  Based on these findings on the role of lipids in virus function and targeting, 
we propose the following suggestions for future research:   
 
1. First, future work should investigate the effect of changing the lipid anchor on the 
extent and stability with which lipid-conjugates associate with the virus surface.  
Virus particles should be modified using lipid anchors of different structure and 
length and visualized using electron microscopy to determine the effect on the 
physical interaction between the lipid conjugate and virus particles.  Furthermore, 
some of our previous studies suggest that when modified viruses are incubated 
in the presence of human plasma (data not shown), the dissociation rate of the 
lipid conjugates from the virus surface was far greater than that in 10% serum in 
PBS.  Therefore, this modification strategy will need to be adjusted for in vivo 
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applications and examining the effect of lipid type and structure of the lipid 
anchor will give insight into improving the lipid anchor design.   
 
2. Second, future work should consider how the physical characteristics of the 
flexible linker would affect virus binding.  One critical function of the flexible linker 
could be to shield the virus particle from binding to the membranes of non-target 
cell types.  Since the first interaction of retroviruses with target cells is the non-
specific adsorption of virus on the cell surface, possibly by via binding to 
proteoglycans and glycosaminoglycans on the cell surface, future work should 
investigate whether this PEG linker can be used to block virus particles from 
binding nonspecifically to these extracellular components.  Virus modification 
using PEG coatings have been attempted before to provide a hydrophilic coat 
which increased blood circulation times and reduced the inflammatory response 
by the host immune system, without affecting the ability of viruses to infect cells.   
The effect of PEG chain length, and the use of branched PEG chains, should be 
explored and their effect on the extent of virus shielding investigated.   
 The effective length of PEG-chains and hence, the extent of shielding they 
provide, depends on the density of chains on the membrane surface and on the 
chain length.  For instance, PEG1900 has a reported effective thickness of 6.5-7 
nm at 9 mol% surface coverage, however at higher densities, 20 mol%, the PEG 
chains take on a fully-extend confirmation, with thickness of 15.8 nm.  As stated 
earlier, the virus envelope protein extends approximately 10 nm from the virus 
surface and therefore, one would expect that using high coverage density may 
block the interaction between virus receptor and its cell receptor altogether.  
However, interestingly, in vivo tests have shown that adenoviruses pegylated 
with 20 kDa chains were able to successful infect cells, possibly because the 
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dynamic forces experienced by the particles in vivo is significantly different than 
in vitro.   Therefore, it would be interesting to determine the extent of which 
nonspecific binding of virus particles can be blocked using the lipid conjugate, 
particularly in vivo.    
 
3. For the future development of this strategy as a tool for creating targeted viruses, 
we must investigate the effect of using targeting moieties other than biotin.  One 
potential strategy may be to use a ligand that preferentially delivers the viral 
vector to the site of diseased cells.  For instance, new vessels in growing tumor 
tissue are formed by the secretion of collagen matrix to allow angiogenesis to 
occur.  Previous studies have shown that viral vectors displaying the collagen-
binding portion of the von Willebrand factor on their surface can selectively 
accumulate at tumors site in vivo.  Although, this protein was originally known to 
facilitate adhesion of platelets to sites of injured epithelium, new insights into the 
biological process involved in tumor growth have led to its successful use in 
tumor tissue targeting.  Thus far, three clinical gene therapy studies have shown 
partial responses and stabilization of the disease.   
 
4. Treatment of virus producer cells with myriocin and fumonisin caused the 
production of virus with altered fusion properties.  Our studies suggest that 
although virus particles are able to bind to cells, they become less fusogenic after 
myriocin treatment, and more fusogenic in response to fumonisin treatment.  
Thus, these results suggest that although both these pharmacological agents 
block de novo sphingolipid biosynthesis, the specific lipid species affected by 
these agents are different and thus elicit distinctly different responses in the virus 
producing cells.   
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 Sphingolipid metabolism or catabolism in mammalian cells has many layers of 
complexity and many times, enzymes involved in these reactions are 
interconnected, regulating not only the levels of the individual bioactive 
sphingolipids species but also their metabolic intermediates.  Many times, when a 
sphingolipid enzyme is implicated in a process, the direct product of this enzyme 
may not be the actual signaling effector.  For instance, sphingomyelinase is an 
enzyme that converts sphingomyelin into ceramide as an immediate lipid product.  
Subsequent action of other enzymes such as ceramidase, sphingomylinase 
synthase or glucosylceramide synthase can convert the ceramide signal to one 
that is mediated by sphingosine, diacylglycerol, or glucosylceramides, 
respectively.  Therefore, it is difficult to implicate one specific lipid species.  
Therefore, in order to understand the specific mechanism behind the decreased 
fusiogenicity after myriocin treatment, and increased fusiogenicity after fumonisin 
treatment, we recommend that future work should investigate the effect on virus 
fusion and infection after exogenous addition of specific glycosphingolipids such 
as sphingomyelin.   
 
5. Previous findings that used pharmacological agents to modify cellular lipid 
synthesis (such as methyl β-cyclodextrin, inhibitors of serine 
palmitoyltransferase, and other inhibitors of sphingolipid biosynthesis), showed 
that these agents can cause fluctuations in the intermediates involved in the lipid 
synthesis pathway, thereby affecting many different functions of the cell.  
Identification of lipid mediators involved in these functions has been difficult 
partially due to the hydrophobic nature of enzymes in sphingolipid metabolism 
and also because most of these sphingolipids are present at very low levels 
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inside the cell.  To address these limitations, in these studies we use highly 
sensitive mass spectrometry methods for sphingolipid analysis.  Furthermore, the 
poor solubility of sphingolipids for delivery of endotoxins or for exogenous 
addition into cells causes problems and many times delivery devices, such as 
albumin conjugates and cyclodextrin loading, must first be optimized and tested.     
Therefore, one suggestion to improve our current system of altering lipid content 
would be to use RNA interference.   
 
6. We found that fumonisin treatment of virus producing cells increased the specific 
infectivity of retroviruses on NIH 3T3 cells and HeLa cells.  Although there was a 
decrease in overall virus production, the infectivity of the virus particles produced 
from this treatment was significantly higher than viruses produced without 
fumonisin treatment.  Since one of the major limitations with producing targeted 
retrovirus vectors is their decreased titer, future work should investigate whether 
treatment of virus producing cells with this pharmacological agent can be used to 
produce more fusogenic virus particles to increase virus infectivity for use in gene 
therapy protocols.    
 
7. In the studies presented in this thesis (Chapter 3, Chapter 4), we observed a cell-
type dependant effect of infectivity of virus with different lipid compositions.  
Future work should investigate whether this difference in infectivity can be used 
as a method of targeting viruses to one cell type versus another.  One 
experiment of interest with the current system could be to co-culture NIH 3T3 
cells and HeLa cells and determine whether the cell type dependant effect on 
infection is transferable when virus particles are exposed to both cell types.  
Initially, we hypothesized that the lipid composition of these two cell types might 
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differ significantly and that these differences might underlie the reason that the 
cell types differed in their susceptibility to infection by myriocin-treated viruses.  
Our lipid analysis suggests, however, that there were only slight differences in 
the levels of ceramides, glucosylceramide, and sphingomyelin present in the lipid 
bilayers of these cells.  Therefore, future work should investigate the mechanism 
behind this cell type dependant decrease in infection, as exhibited by virus 
particles treated with myriocin, and whether this mechanism can be used to help 
produce viruses that are more infectious to clinically relevant cells types (such as 
hematopoietic stem cells, embryonic stem cells, breast cancer cells, neurons, 
etc.).   
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APPENDIX A.1 





1. Remove unreacted PEG chains 
2. Make various dilutions of biotin-PEG-virus from a pre-determined conc of virus-
titer. 
3. Add samples to strep-avidan plates (96wells) with standard samples of specific 
concentration of biotin-PEG for 1hour, at 37OC. 
Make samples in Tris-buffered saline, TBS (pH 7.4) + 0.1% BSA. 
4. Wash with 300ul TBS + 0.1% BSA + 0.05% Tween-20:  wash 3x with 5 min 
incubation between washes at 15-25o.  
5. Apply blocking buffer for 30min at 37OC; 5% BSA + TBS 
6. Incubate with anti-biotin POD Fab antibody at 1:1000 dilution for 1hour at 37OC. 
7. Wash plate with TBS + 0.1% BSA + 0.05% Tween-20; wash 3x with 5 min 
incubation between washes at 15-25o.  
8. Add ABTS (Pierce) 
9. Read at 405 nm on plate reader.  May take 10-30 min to develop; add 0.5 % 
SDS for reliable endpoint measurement. 
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APPENDIX A.2 





- We tried to approach this by measuring the radius of gyration using AFFF.   
- In AFFF, a cross flow is used to push the colloids onto a membrane. Diffusion 
processes act against the external field so the colloids move towards the middle 
of the channel.  
- An axial flow is then switched on allowing smaller particles to elute faster than 
the larger particles.  A detector was set up to measure elution times and the 
radius of gyration was calculated.  (SOFTWARE NAME) 
- We took stocks of lacZ amphotropic retrovirus, mixed them with the lipid 
conjugate, and incubated for 2 hours at 4 deg.  The unmodified control was 
incubated with TBS only.   
- Polybrene was used to remove free lipid and the resulting pellets were analyzed 
using AFFF to measure radius of gyration, that is the radial distribution of mass 
of a particle.  Elution time and focus flow rates were optimized to achieve good 
separation of the sample.   
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TECHNOLOGICAL INNOVATION: GENERATING ECONOMIC RESULTS (TI: GER®) 
 
B.1 Project Description:  
 During my time at Georgia Tech, I had the opportunity to be admitted into the 
TI:GER program.  This program is offered by the School of Management and is a 
collaboration between Georgia Tech and Emory University, School of Law.  This is a one 
of a kind program that brings together PhD students, MBA students and Law students to 
create multifunctional teams to help them learn about the challenges of bringing their 
new technologies into the market.  During this time, I had the opportunity to work with 
many talented students and meet many executives involved in different steps of the 
commercialization process.  My team and I competed in three business plan 
competitions: New Ventures Business Plan Competition 2007 (2nd place winner), Lunar 
Ventures 2008 (1st place runner-up) and the Tyler New Ventures Business Plan 
Competition (3rd place winner).  We had some success in raising funding and more 
importantly interest in this technology.  Overall, this was a great opportunity to get first -
hand experience in the challenges involved with start-up technologies.   
 
B.2 Invention Description:  
 The present invention proposes a methodology for the manipulation of virus 
particles for their use in gene transfer, virus detection, virus targeting, evasion of the 
immune response, or any application which requires the modification of the surfaces of 
viruses. 
 The current invention uses retroviruses as the vehicle for gene transfer.  
Recombinant retroviruses are commonly used in gene therapy clinical trials because 
they can permanently integrate a therapeutic gene into the DNA of target cells, resulting 
in a long-term cure.  Retroviral-mediated gene transfer can be used to treat inherited 
genetic disorders, complex genetic disorders, and infectious diseases, and has 
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numerous applications in tissue engineering.  One major shortcoming of virtually all 
methods of gene transfer is the inability to strictly control their tropism, the types of cells 
to which they are able to transfer genes.  For many applications, particularly for most in 
vivo gene therapies, the tropism of gene transfer vectors needs to be narrowed so that 
genes are transferred only to the cells and tissues of interest and to no others.  For other 
applications, such as in cystic fibrosis gene therapy, the tropism of gene transfer vectors 
needs to be expanded so that genes can be transferred to the cell types of interest.   
  
The current invention uses a novel tripartite system to increase the specificity with which 
viruses bind to target cells.  First, a lipid based conjugate allows for quick and efficient 
integration into the virus surface, which is composed of a lipid bilayer.  Second, the poly-
ethylene glycol (PEG) linker allows for the increased biocompatibility of the virus such 
that the virus particles are able to evade a large immune response.  Third, a specific 
ligand attached to PEG molecules allows for increased targeting capabilities such that 
the virus only interacts with cells that exhibit a complimentary receptor.  This ligand will 
be disease dependant and may change depending on the desired dose of ‘genes’ that 
need to be delivered.  This tripartite system, a lipid conjugated to a PEG molecule with a 
specific ligand, will be reacted with virus particles so the virus’ tropism is affected. 
 
B.3 Executive Summary:  
ViraTag LLC is a start up venture and our goal is to bring our patent-pending 
technology into the viral diagnostic market to facilitate the rapid detection of human viral 
infections in plasma.  ViraTag’s first product launch will be a kit for diagnosing the HIV 
virus.  Our patent pending technology will be incorporated into an HIV Diagnostic Kit that 
will set the standard for next generation HIV diagnostics.    
As of today, doctors using HIV kits on the market are not able to diagnose a patient 
with HIV until six months after exposure to the virus.  ViraTag’s HIV Diagnostic kit will 
allow accurate detection of HIV four times faster, giving patients the ability to seek 
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treatment earlier, have a better quality of life, and stop the spread of HIV, while saving 
the healthcare industry billions of dollars.   ViraTag provides an exciting investment 
opportunity for any potential investor.   
• The Opportunity:  Today, if a patient goes to the doctor a day after being 
exposed to the HIV virus, the doctor will tell them, “Come back in six months to be 
tested.”   The use of ViraTag’s HIV diagnostic will allow a doctor to tell the patient 
“Come back in six weeks to be tested.”   Currently, the HIV diagnostic kits in the 
market are not sensitive enough to detect HIV early in the infection cycle.   Yet, 
patients need to learn of HIV infection early in the infection cycle in order to have 
a better quality of life and to avoid spreading the virus.  As a result, doctors and 
commercial laboratories need the ability to diagnose individuals with HIV as early 
as possible, and they need the kits to be cost-effective.   Moreover, governments, 
the healthcare industry, and insurance providers will reap the benefits of early 
detection.   Studies show that early detection of HIV will save these parties billions 
of dollars. 
• ViraTag’s Solution:  ViraTag patent-pending technology can diagnose the 
presence of viruses like HIV with a 17-fold increase in sensitivity, a ten-fold 
reduction in costs, and an overall reduction in the time it takes to conduct the test 
from 6 – 8 days down to 30 minutes without the use of highly trained personnel.  
This means that ViraTag Diagnostic Kits can detect the HIV virus starting at six 
weeks into the infection cycle, while reducing costs from $200 dollars per kit to 
$10 per kit and saving labor costs associated with highly trained technicians. 
• The Competition:   ViraTag’s competition is relatively strong.  Roche holds a 
dominant position with respect to molecular testing of HIV in the US at about 50% 
of the market.  Chiron is also developing a molecular test for HIV but is currently 
available for use in a research setting only.   Minor competitors include Abbott, 
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J&J, and Beckman Dickinson, with a combined 40% of market share. Affymetrix is 
a recent entry to the market.  It has a proprietary technology called GeneChip 
which detects HIV strains.   But Affymetrix’s technology is only being used in a 
research setting, though we are watching it closely.   Since a high degree of 
biological information can be gained from GeneChips, they are likely to have a 
major impact on the way HIV is clinically managed.  
• The Technology and ViraTag’s Competitive Advantage:  ViraTag’s diagnostic 
kits are based on a proprietary, patent-pending technology that specifically and 
accurately tags viruses so they can be identified if present in blood samples.  The 
viruses are tagged with a fluorescent marker that is observable under a 
microscope.  Our competitive advantage lies in the fact that we will be a first 
mover with enforceable intellectual property.  
• The Market:  ViraTag’s target market is people who have potentially been 
exposed to the HIV virus.  These people are typically between the ages of 18 and 
49.   We are initially targeting developed nations, including the U.S, Europe, 
China, and India, but will target developing nations as we expand our market 
share.  In vitro Diagnostics is a $45 billion market.   Within this market, the HIV 
diagnostics market is worth $8.57 billion and is rapidly growing at a Compound 
Annual Growth Rate of 17.79%.   In the U.S., 60 million HIV tests were 
administered last year.    Additionally, this is an ideal time for entry of an 
innovative HIV diagnostics product in the market because the patent on the 
current dominant technology has recently expired.  
• Marketing Strategy and Business Model:  In this industry, it is typical for 
emerging companies like ViraTag to a first partner with a global diagnostics 
company—an alliance partner—for regulatory navigation, manufacturing, and 
product distribution.  Therefore, we will generate a prototype, and will outsource 
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manufacturing to a business partner.  Based on this marketing strategy, we 
conservatively estimate our market penetration at 7% (partnering with Abbott), but 
we are optimistic that our target penetration will approach 50% (partnering with 
Roche).   ViraTag shall follow this business model for the HIV kits.  However, 
once ViraTag has a footing in the HIV market, we will manufacture our own 
diagnostic kits for viruses like Hepatitis C and B with the cash inflow generated 
from the HIV kits.   
• Risk and FDA Approval:  ViraTag’s diagnostic kits fall into the Category II of 
FDA in vitro diagnostic kits, one category above items like band-aids.  ViraTag 
will work with an alliance partner to complete the approval process in between 
nine to twelve months. 
 
 
